


<!DOCTYPE html>
<html lang="en-CA">
  <head>
    <title>
    Type 2 diabetes: non-insulin pharmacotherapy |     Centre for Effective Practice - Digital Tools        </title>
  <meta charset="UTF-8" />
<script type="text/javascript">
/* <![CDATA[ */
var gform;gform||(document.addEventListener("gform_main_scripts_loaded",function(){gform.scriptsLoaded=!0}),document.addEventListener("gform/theme/scripts_loaded",function(){gform.themeScriptsLoaded=!0}),window.addEventListener("DOMContentLoaded",function(){gform.domLoaded=!0}),gform={domLoaded:!1,scriptsLoaded:!1,themeScriptsLoaded:!1,isFormEditor:()=>"function"==typeof InitializeEditor,callIfLoaded:function(o){return!(!gform.domLoaded||!gform.scriptsLoaded||!gform.themeScriptsLoaded&&!gform.isFormEditor()||(gform.isFormEditor()&&console.warn("The use of gform.initializeOnLoaded() is deprecated in the form editor context and will be removed in Gravity Forms 3.1."),o(),0))},initializeOnLoaded:function(o){gform.callIfLoaded(o)||(document.addEventListener("gform_main_scripts_loaded",()=>{gform.scriptsLoaded=!0,gform.callIfLoaded(o)}),document.addEventListener("gform/theme/scripts_loaded",()=>{gform.themeScriptsLoaded=!0,gform.callIfLoaded(o)}),window.addEventListener("DOMContentLoaded",()=>{gform.domLoaded=!0,gform.callIfLoaded(o)}))},hooks:{action:{},filter:{}},addAction:function(o,r,e,t){gform.addHook("action",o,r,e,t)},addFilter:function(o,r,e,t){gform.addHook("filter",o,r,e,t)},doAction:function(o){gform.doHook("action",o,arguments)},applyFilters:function(o){return gform.doHook("filter",o,arguments)},removeAction:function(o,r){gform.removeHook("action",o,r)},removeFilter:function(o,r,e){gform.removeHook("filter",o,r,e)},addHook:function(o,r,e,t,n){null==gform.hooks[o][r]&&(gform.hooks[o][r]=[]);var d=gform.hooks[o][r];null==n&&(n=r+"_"+d.length),gform.hooks[o][r].push({tag:n,callable:e,priority:t=null==t?10:t})},doHook:function(r,o,e){var t;if(e=Array.prototype.slice.call(e,1),null!=gform.hooks[r][o]&&((o=gform.hooks[r][o]).sort(function(o,r){return o.priority-r.priority}),o.forEach(function(o){"function"!=typeof(t=o.callable)&&(t=window[t]),"action"==r?t.apply(null,e):e[0]=t.apply(null,e)})),"filter"==r)return e[0]},removeHook:function(o,r,t,n){var e;null!=gform.hooks[o][r]&&(e=(e=gform.hooks[o][r]).filter(function(o,r,e){return!!(null!=n&&n!=o.tag||null!=t&&t!=o.priority)}),gform.hooks[o][r]=e)}});
/* ]]> */
</script>

  <meta name="viewport" content="width=device-width" />
  <meta name="theme-color" content="#999999" />
  <link href="https://fonts.googleapis.com/css?family=Montserrat:500,500i,700,700i|Open+Sans:400,400i,700,700i&display=swap" rel="stylesheet">
  <meta name='robots' content='noindex, nofollow' />
	<style>img:is([sizes="auto" i], [sizes^="auto," i]) { contain-intrinsic-size: 3000px 1500px }</style>
	<link rel='dns-prefetch' href='//a.omappapi.com' />
<link rel='dns-prefetch' href='//www.googletagmanager.com' />
		<!-- This site uses the Google Analytics by MonsterInsights plugin v9.5.3 - Using Analytics tracking - https://www.monsterinsights.com/ -->
							<script src="//www.googletagmanager.com/gtag/js?id=G-G1F4BDXK7E"  data-cfasync="false" data-wpfc-render="false" type="text/javascript" async></script>
			<script data-cfasync="false" data-wpfc-render="false" type="text/javascript">
				var mi_version = '9.5.3';
				var mi_track_user = true;
				var mi_no_track_reason = '';
								var MonsterInsightsDefaultLocations = {"page_location":"https:\/\/tools.cep.health\/tool\/type-2-diabetes-non-insulin-pharmacotherapy-2\/"};
				if ( typeof MonsterInsightsPrivacyGuardFilter === 'function' ) {
					var MonsterInsightsLocations = (typeof MonsterInsightsExcludeQuery === 'object') ? MonsterInsightsPrivacyGuardFilter( MonsterInsightsExcludeQuery ) : MonsterInsightsPrivacyGuardFilter( MonsterInsightsDefaultLocations );
				} else {
					var MonsterInsightsLocations = (typeof MonsterInsightsExcludeQuery === 'object') ? MonsterInsightsExcludeQuery : MonsterInsightsDefaultLocations;
				}

								var disableStrs = [
										'ga-disable-G-G1F4BDXK7E',
									];

				/* Function to detect opted out users */
				function __gtagTrackerIsOptedOut() {
					for (var index = 0; index < disableStrs.length; index++) {
						if (document.cookie.indexOf(disableStrs[index] + '=true') > -1) {
							return true;
						}
					}

					return false;
				}

				/* Disable tracking if the opt-out cookie exists. */
				if (__gtagTrackerIsOptedOut()) {
					for (var index = 0; index < disableStrs.length; index++) {
						window[disableStrs[index]] = true;
					}
				}

				/* Opt-out function */
				function __gtagTrackerOptout() {
					for (var index = 0; index < disableStrs.length; index++) {
						document.cookie = disableStrs[index] + '=true; expires=Thu, 31 Dec 2099 23:59:59 UTC; path=/';
						window[disableStrs[index]] = true;
					}
				}

				if ('undefined' === typeof gaOptout) {
					function gaOptout() {
						__gtagTrackerOptout();
					}
				}
								window.dataLayer = window.dataLayer || [];

				window.MonsterInsightsDualTracker = {
					helpers: {},
					trackers: {},
				};
				if (mi_track_user) {
					function __gtagDataLayer() {
						dataLayer.push(arguments);
					}

					function __gtagTracker(type, name, parameters) {
						if (!parameters) {
							parameters = {};
						}

						if (parameters.send_to) {
							__gtagDataLayer.apply(null, arguments);
							return;
						}

						if (type === 'event') {
														parameters.send_to = monsterinsights_frontend.v4_id;
							var hookName = name;
							if (typeof parameters['event_category'] !== 'undefined') {
								hookName = parameters['event_category'] + ':' + name;
							}

							if (typeof MonsterInsightsDualTracker.trackers[hookName] !== 'undefined') {
								MonsterInsightsDualTracker.trackers[hookName](parameters);
							} else {
								__gtagDataLayer('event', name, parameters);
							}
							
						} else {
							__gtagDataLayer.apply(null, arguments);
						}
					}

					__gtagTracker('js', new Date());
					__gtagTracker('set', {
						'developer_id.dZGIzZG': true,
											});
					if ( MonsterInsightsLocations.page_location ) {
						__gtagTracker('set', MonsterInsightsLocations);
					}
										__gtagTracker('config', 'G-G1F4BDXK7E', {"forceSSL":"true","link_attribution":"true","page_path":location.pathname + location.search + location.hash} );
															window.gtag = __gtagTracker;										(function () {
						/* https://developers.google.com/analytics/devguides/collection/analyticsjs/ */
						/* ga and __gaTracker compatibility shim. */
						var noopfn = function () {
							return null;
						};
						var newtracker = function () {
							return new Tracker();
						};
						var Tracker = function () {
							return null;
						};
						var p = Tracker.prototype;
						p.get = noopfn;
						p.set = noopfn;
						p.send = function () {
							var args = Array.prototype.slice.call(arguments);
							args.unshift('send');
							__gaTracker.apply(null, args);
						};
						var __gaTracker = function () {
							var len = arguments.length;
							if (len === 0) {
								return;
							}
							var f = arguments[len - 1];
							if (typeof f !== 'object' || f === null || typeof f.hitCallback !== 'function') {
								if ('send' === arguments[0]) {
									var hitConverted, hitObject = false, action;
									if ('event' === arguments[1]) {
										if ('undefined' !== typeof arguments[3]) {
											hitObject = {
												'eventAction': arguments[3],
												'eventCategory': arguments[2],
												'eventLabel': arguments[4],
												'value': arguments[5] ? arguments[5] : 1,
											}
										}
									}
									if ('pageview' === arguments[1]) {
										if ('undefined' !== typeof arguments[2]) {
											hitObject = {
												'eventAction': 'page_view',
												'page_path': arguments[2],
											}
										}
									}
									if (typeof arguments[2] === 'object') {
										hitObject = arguments[2];
									}
									if (typeof arguments[5] === 'object') {
										Object.assign(hitObject, arguments[5]);
									}
									if ('undefined' !== typeof arguments[1].hitType) {
										hitObject = arguments[1];
										if ('pageview' === hitObject.hitType) {
											hitObject.eventAction = 'page_view';
										}
									}
									if (hitObject) {
										action = 'timing' === arguments[1].hitType ? 'timing_complete' : hitObject.eventAction;
										hitConverted = mapArgs(hitObject);
										__gtagTracker('event', action, hitConverted);
									}
								}
								return;
							}

							function mapArgs(args) {
								var arg, hit = {};
								var gaMap = {
									'eventCategory': 'event_category',
									'eventAction': 'event_action',
									'eventLabel': 'event_label',
									'eventValue': 'event_value',
									'nonInteraction': 'non_interaction',
									'timingCategory': 'event_category',
									'timingVar': 'name',
									'timingValue': 'value',
									'timingLabel': 'event_label',
									'page': 'page_path',
									'location': 'page_location',
									'title': 'page_title',
									'referrer' : 'page_referrer',
								};
								for (arg in args) {
																		if (!(!args.hasOwnProperty(arg) || !gaMap.hasOwnProperty(arg))) {
										hit[gaMap[arg]] = args[arg];
									} else {
										hit[arg] = args[arg];
									}
								}
								return hit;
							}

							try {
								f.hitCallback();
							} catch (ex) {
							}
						};
						__gaTracker.create = newtracker;
						__gaTracker.getByName = newtracker;
						__gaTracker.getAll = function () {
							return [];
						};
						__gaTracker.remove = noopfn;
						__gaTracker.loaded = true;
						window['__gaTracker'] = __gaTracker;
					})();
									} else {
										console.log("");
					(function () {
						function __gtagTracker() {
							return null;
						}

						window['__gtagTracker'] = __gtagTracker;
						window['gtag'] = __gtagTracker;
					})();
									}
			</script>
				<!-- / Google Analytics by MonsterInsights -->
		<link rel='stylesheet' id='wp-block-library-css' href='https://tools.cep.health/wp-includes/css/dist/block-library/style.min.css?ver=6.8.2' media='all' />
<style id='classic-theme-styles-inline-css' type='text/css'>
/*! This file is auto-generated */
.wp-block-button__link{color:#fff;background-color:#32373c;border-radius:9999px;box-shadow:none;text-decoration:none;padding:calc(.667em + 2px) calc(1.333em + 2px);font-size:1.125em}.wp-block-file__button{background:#32373c;color:#fff;text-decoration:none}
</style>
<style id='global-styles-inline-css' type='text/css'>
:root{--wp--preset--aspect-ratio--square: 1;--wp--preset--aspect-ratio--4-3: 4/3;--wp--preset--aspect-ratio--3-4: 3/4;--wp--preset--aspect-ratio--3-2: 3/2;--wp--preset--aspect-ratio--2-3: 2/3;--wp--preset--aspect-ratio--16-9: 16/9;--wp--preset--aspect-ratio--9-16: 9/16;--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;--wp--preset--spacing--20: 0.44rem;--wp--preset--spacing--30: 0.67rem;--wp--preset--spacing--40: 1rem;--wp--preset--spacing--50: 1.5rem;--wp--preset--spacing--60: 2.25rem;--wp--preset--spacing--70: 3.38rem;--wp--preset--spacing--80: 5.06rem;--wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);--wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);--wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);--wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1), 6px 6px rgba(0, 0, 0, 1);--wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);}:where(.is-layout-flex){gap: 0.5em;}:where(.is-layout-grid){gap: 0.5em;}body .is-layout-flex{display: flex;}.is-layout-flex{flex-wrap: wrap;align-items: center;}.is-layout-flex > :is(*, div){margin: 0;}body .is-layout-grid{display: grid;}.is-layout-grid > :is(*, div){margin: 0;}:where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;}:where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;}
:where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;}
:where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;}
:root :where(.wp-block-pullquote){font-size: 1.5em;line-height: 1.6;}
</style>
<link rel='stylesheet' id='studio123_styles-css' href='https://tools.cep.health/wp-content/themes/cep-tools/style.min.css?ver=1743561782' media='all' />
<link rel='stylesheet' id='glossary-hint-css' href='https://tools.cep.health/wp-content/plugins/glossary-by-codeat/assets/css/tooltip-classic.css?ver=2.3.5' media='all' />
<script type="text/javascript" src="https://tools.cep.health/wp-content/plugins/google-analytics-for-wordpress/assets/js/frontend-gtag.min.js?ver=9.5.3" id="monsterinsights-frontend-script-js" async="async" data-wp-strategy="async"></script>
<script data-cfasync="false" data-wpfc-render="false" type="text/javascript" id='monsterinsights-frontend-script-js-extra'>/* <![CDATA[ */
var monsterinsights_frontend = {"js_events_tracking":"true","download_extensions":"doc,pdf,ppt,zip,xls,docx,pptx,xlsx","inbound_paths":"[{\"path\":\"\\\/go\\\/\",\"label\":\"affiliate\"},{\"path\":\"\\\/recommend\\\/\",\"label\":\"affiliate\"}]","home_url":"https:\/\/tools.cep.health","hash_tracking":"true","v4_id":"G-G1F4BDXK7E"};/* ]]> */
</script>

<!-- Google tag (gtag.js) snippet added by Site Kit -->

<!-- Google Analytics snippet added by Site Kit -->
<script type="text/javascript" src="https://www.googletagmanager.com/gtag/js?id=GT-MBGGM43" id="google_gtagjs-js" async></script>
<script type="text/javascript" id="google_gtagjs-js-after">
/* <![CDATA[ */
window.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments);}
gtag("set","linker",{"domains":["tools.cep.health"]});
gtag("js", new Date());
gtag("set", "developer_id.dZTNiMT", true);
gtag("config", "GT-MBGGM43");
/* ]]> */
</script>

<!-- End Google tag (gtag.js) snippet added by Site Kit -->
<script type="text/javascript" src="https://tools.cep.health/wp-content/themes/cep-tools/js/jquery.min.js" id="jquery-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-content/themes/cep-tools/js/jquery-migrate.min.js" id="jquery-migrate-js"></script>
<link rel="https://api.w.org/" href="https://tools.cep.health/wp-json/" /><link rel="alternate" title="JSON" type="application/json" href="https://tools.cep.health/wp-json/wp/v2/tools/58846" /><link rel="alternate" title="oEmbed (JSON)" type="application/json+oembed" href="https://tools.cep.health/wp-json/oembed/1.0/embed?url=https%3A%2F%2Ftools.cep.health%2Ftool%2Ftype-2-diabetes-non-insulin-pharmacotherapy-2%2F" />
<link rel="alternate" title="oEmbed (XML)" type="text/xml+oembed" href="https://tools.cep.health/wp-json/oembed/1.0/embed?url=https%3A%2F%2Ftools.cep.health%2Ftool%2Ftype-2-diabetes-non-insulin-pharmacotherapy-2%2F&#038;format=xml" />
<meta name="generator" content="Site Kit by Google 1.155.0" />
<!-- Google Tag Manager snippet added by Site Kit -->
<script type="text/javascript">
/* <![CDATA[ */

			( function( w, d, s, l, i ) {
				w[l] = w[l] || [];
				w[l].push( {'gtm.start': new Date().getTime(), event: 'gtm.js'} );
				var f = d.getElementsByTagName( s )[0],
					j = d.createElement( s ), dl = l != 'dataLayer' ? '&l=' + l : '';
				j.async = true;
				j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl;
				f.parentNode.insertBefore( j, f );
			} )( window, document, 'script', 'dataLayer', 'GTM-WLFDZV' );
			
/* ]]> */
</script>

<!-- End Google Tag Manager snippet added by Site Kit -->
<link rel="icon" href="https://tools.cep.health/wp-content/uploads/2019/10/cropped-Frame-36-1-32x32.png" sizes="32x32" />
<link rel="icon" href="https://tools.cep.health/wp-content/uploads/2019/10/cropped-Frame-36-1-192x192.png" sizes="192x192" />
<link rel="apple-touch-icon" href="https://tools.cep.health/wp-content/uploads/2019/10/cropped-Frame-36-1-180x180.png" />
<meta name="msapplication-TileImage" content="https://tools.cep.health/wp-content/uploads/2019/10/cropped-Frame-36-1-270x270.png" />
		<style type="text/css" id="wp-custom-css">
			.m0 {margin-top:0; margin-bottom: 0}		</style>
		<!--- Error: No Google analytics ID found. Go to Site Options > Analytics to enter your ID. ---><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({"gtm.start":new Date().getTime(),event:"gtm.js"});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!="dataLayer"?"&l="+l:"";j.async=true;j.src="https://www.googletagmanager.com/gtm.js?id="+i+dl;f.parentNode.insertBefore(j,f);})(window,document,"script","dataLayer","GTM-K6HPX8H");</script>  </head>
  <body class="wp-singular tools-template-default single single-tools postid-58846 wp-theme-cep-tools type-2-diabetes-non-insulin-pharmacotherapy-2">

      <!-- Google Tag Manager (noscript) -->
    <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-K6HPX8H"
    height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
    <!-- End Google Tag Manager (noscript) -->

    <header>
      <div class="container">
        <div class="columns is-flex is-gapless">
          <div class="column">
            <a class="logo" target="_self" href="https://cep.health/tools" data-wpel-link="external" rel="external noopener noreferrer">
              <img src="https://tools.cep.health/wp-content/themes/cep-tools/img/logo.svg" alt="Centre for Effective Practice - Digital Tools" />
            </a>
          </div>
        </div>
      </div>
    </header>

<main>
  	<section class="section--impact_area">
    <div class="container">
        <h1>Type 2 diabetes: non-insulin pharmacotherapy</h1>
                    <p class="last-updated"><i class="icon icon-clock-with-arrow"> </i>Last Updated: June 23, 2023</p>
                <ul class="links">
            <li>
                <button data-search-content class="button">Search Content&nbsp;&nbsp;<i class="icon icon-search"></i></a>
            </li>
                    </ul>
    </div>
</section>

		<section class="section--sections_listing" id="sections">

			
<div class="search-tool">
    <div class="search-tool-bar">
        <div class="search-wrapper">
            <div class="search-input-wrapper">
                <input data-search-tool-input type="search" autocomplete="off" placeholder="Enter search terms">
                <i class="icon icon-search"></i>
                <span class="search-no-results-found">No Results Found</span>
                <span class="search-result-count"><span class="current">0</span>/<span class="total">0</span></span>
            </div>
            <button data-search-previous disabled class="search-previous"><i class="icon icon-chevron-up"></i></button>
            <button data-search-next disabled class="search-next"><i class="icon icon-chevron-down"></i></button>
        </div>
        <button data-search-tool-close class="close"><i class="icon icon-close"></i></button>
    </div>
</div>
			<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>This tool is designed to support primary care providers to prescribe and manage non-insulin pharmacotherapy for adult patients living with type 2 diabetes. This is an update of the original Achieving glycemic control in type 2 diabetes tool, released in 2012.</p>
</div></article>

<article class="block--background  core-block" data-block-name="cep/background"><div class="container">
<div class="wp-block-cep-background is-style-blue-background"><article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <h6><a href="https://cep.health/academic-detailing/" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Sign up for virtual academic detailing (one-on-one education) on this topic</a></h6>
          </div>
        </div>

      </div>
</article></div>
</div></article>			<div class="container has-text-right" style="padding: 0 0 1.5rem;">
				<div class="expand-all">
					<a href="#" data-expand-text="Expand All" data-collapse-text="Collapse All">Expand All</a>
				</div>
			</div>
			<div id="top-of-sections"></div>
							<section class="main-section" id="diagnosis" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Diagnosis								
    <span class="badge new" data-last-modified="Jun 23, 2023" data-hide-on-click>New</span>
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h4 class="wp-block-heading">Diagnostic criteria for diabetes <sup>1</sup></h4>
</div></article>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-1.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <ul>
<li><strong>Fasting plasma glucose</strong> (FPG) ≥7.0 mmol/L<sup>*</sup>; OR</li>
<li><strong>A1C</strong> ≥6.5%<sup>†</sup>; OR</li>
<li><strong>2-hour plasma glucose</strong> (2hPG) in a 75g <strong>oral glucose tolerance test</strong> (OGTT) ≥11.1 mmol/L; OR</li>
<li><strong>Random<sup>‡</sup> plasma glucose</strong> (PG) ≥11.1 mmol/L</li>
</ul>
          </div>
        </div>

      </div>
</article></div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2020/05/info-icon.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>The decision of which test to use for diabetes diagnosis is left to clinical judgment. Each diagnostic test has <a href="https://link.cep.health/t2dmnihtml1" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">advantages and disadvantages.<sup>2</sup></a></p>
          </div>
        </div>

      </div>
</article></div>
</div>


<article class="block--background  core-block" data-block-name="cep/background"><div class="container">
<div class="wp-block-cep-background is-style-blue-background"><article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading">Diagnosis of diabetes is confirmed if:</h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Symptomatic hyperglycemia is present (therefore confirmatory tests are not required); OR</li>



<li>The results of two laboratory tests are in the diabetes range (in the absence of symptomatic hyperglycemia)<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>The second confirmatory laboratory test must be done on another day, and  it is preferable that the same test be repeated for confirmation (in a  timely fashion, based on clinical judgment), with the exception of  random PG.</li>
</ul>
</div></article></li>
</ul>
</div></article></div>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p><sub>* = fasting – no caloric intake for at least 8 hours; † = using a standardized, validated assay in the absence of factors that affect the accuracy of the A1C; ‡ = random – anytime of the day, without regard to the interval since the last meal</sub></p>
</div></article>						</div>
					</div>
				</section>
							<section class="main-section" id="individualizing-a1c-targets" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Individualizing A1C targets								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Yellow-Notice.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <h6>Factors that affect A1C:<sup>1</sup></h6>
<ul>
<li><strong>Factors that can increase A1C</strong>: iron deficiency, B12 deficiency, <span style="font-weight: 400;">↓</span> erythropoiesis, alcoholism, chronic renal failure, splenectomy</li>
<li><strong>Factors that can decrease A1C</strong>: use of erythropoietin, iron or B12, reticulocytosis, chronic liver disease, ingestion of acetylsalicylic acid, vitamin C/E, decreased erythrocyte lifespan (e.g., chronic renal failure, hemoglobinopathies, splenomegaly, rheumatoid arthritis, antiretrovirals, ribavirin, dapsone)</li>
</ul>
          </div>
        </div>

      </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">A1C targets and considerations for glycemic control <sup>1,3-12</sup></h3>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p></p>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-1.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <h6><strong>Individualize (and reassess) targets</strong></h6>
<p>Use <a href="https://link.cep.health/t2dmnihtml26" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">this practice aid</a> to individualize the patient&#8217;s A1C target</p>
<p>Consider potential benefits and harms to the patient according to each patient&#8217;s:</p>
<div style="width: 35%; padding: 0 20px 0 0; float: left;">
<ul>
<li>Age and/or frailty</li>
<li>Comorbidities</li>
<li>Prognosis</li>
<li>Duration of diabetes</li>
</ul>
</div>
<div style="width: 55%; padding: 0 0px 0 0; float: right;">
<ul>
<li>Risk of hypoglycemia</li>
<li>Patient preferences resources and support system</li>
<li>Number, complexity and burden of medications</li>
</ul>
</div>
<p>&nbsp;</p>
<p>&nbsp;</p>
          </div>
        </div>

      </div>
</article>

<article class="block--image  core-block" data-block-name="core/image"><div class="container">
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="4893" height="3463" src="https://tools.cep.health/wp-content/uploads/2024/10/Glycemic-control-2.png" alt="" class="wp-image-66755" srcset="https://tools.cep.health/wp-content/uploads/2024/10/Glycemic-control-2.png 4893w, https://tools.cep.health/wp-content/uploads/2024/10/Glycemic-control-2-300x212.png 300w, https://tools.cep.health/wp-content/uploads/2024/10/Glycemic-control-2-1024x725.png 1024w, https://tools.cep.health/wp-content/uploads/2024/10/Glycemic-control-2-768x544.png 768w, https://tools.cep.health/wp-content/uploads/2024/10/Glycemic-control-2-1536x1087.png 1536w, https://tools.cep.health/wp-content/uploads/2024/10/Glycemic-control-2-2048x1449.png 2048w, https://tools.cep.health/wp-content/uploads/2024/10/Glycemic-control-2-2035x1440.png 2035w, https://tools.cep.health/wp-content/uploads/2024/10/Glycemic-control-2-1526x1080.png 1526w, https://tools.cep.health/wp-content/uploads/2024/10/Glycemic-control-2-1017x720.png 1017w, https://tools.cep.health/wp-content/uploads/2024/10/Glycemic-control-2-640x453.png 640w" sizes="auto, (max-width: 4893px) 100vw, 4893px" /></figure>
</div></article>

<article class="block--image  core-block" data-block-name="core/image"><div class="container">
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="426" src="https://tools.cep.health/wp-content/uploads/2024/10/A1c-Chart-1024x426.jpg" alt="" class="wp-image-66748" srcset="https://tools.cep.health/wp-content/uploads/2024/10/A1c-Chart-1024x426.jpg 1024w, https://tools.cep.health/wp-content/uploads/2024/10/A1c-Chart-300x125.jpg 300w, https://tools.cep.health/wp-content/uploads/2024/10/A1c-Chart-768x320.jpg 768w, https://tools.cep.health/wp-content/uploads/2024/10/A1c-Chart-1536x640.jpg 1536w, https://tools.cep.health/wp-content/uploads/2024/10/A1c-Chart-2048x853.jpg 2048w, https://tools.cep.health/wp-content/uploads/2024/10/A1c-Chart-1920x800.jpg 1920w, https://tools.cep.health/wp-content/uploads/2024/10/A1c-Chart-1280x533.jpg 1280w, https://tools.cep.health/wp-content/uploads/2024/10/A1c-Chart-640x267.jpg 640w" sizes="auto, (max-width: 1024px) 100vw, 1024px" /></figure>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p class="has-text-align-left has-small-font-size"><em><strong>Note</strong>: A1C tends to rise over time, even for patients on stable treatments</em>. </p>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p class="has-text-align-left has-small-font-size">*Lower limit may not be necessary in patients using low-intensity treatment. Consider risks and expected benefits on a case-by-case basis.</p>
</div></article>						</div>
					</div>
				</section>
							<section class="main-section" id="approach-to-selecting-antihyperglycemic-agents" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Approach to selecting antihyperglycemic agents								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--form  core-block" data-block-name="gravityforms/form"><div class="container">
                <div class='gf_browser_unknown gform_wrapper gform-theme gform-theme--foundation gform-theme--framework gform-theme--orbital hide-submit-button_wrapper' data-form-theme='orbital' data-form-index='0' id='gform_wrapper_42' style='display:none'><style>#gform_wrapper_42[data-form-index="0"].gform-theme,[data-parent-form="42_0"]{--gf-color-primary: #204ce5;--gf-color-primary-rgb: 32, 76, 229;--gf-color-primary-contrast: #fff;--gf-color-primary-contrast-rgb: 255, 255, 255;--gf-color-primary-darker: #001AB3;--gf-color-primary-lighter: #527EFF;--gf-color-secondary: #fff;--gf-color-secondary-rgb: 255, 255, 255;--gf-color-secondary-contrast: #112337;--gf-color-secondary-contrast-rgb: 17, 35, 55;--gf-color-secondary-darker: #F5F5F5;--gf-color-secondary-lighter: #FFFFFF;--gf-color-out-ctrl-light: rgba(17, 35, 55, 0.1);--gf-color-out-ctrl-light-rgb: 17, 35, 55;--gf-color-out-ctrl-light-darker: rgba(104, 110, 119, 0.35);--gf-color-out-ctrl-light-lighter: #F5F5F5;--gf-color-out-ctrl-dark: #585e6a;--gf-color-out-ctrl-dark-rgb: 88, 94, 106;--gf-color-out-ctrl-dark-darker: #112337;--gf-color-out-ctrl-dark-lighter: rgba(17, 35, 55, 0.65);--gf-color-in-ctrl: #fff;--gf-color-in-ctrl-rgb: 255, 255, 255;--gf-color-in-ctrl-contrast: #112337;--gf-color-in-ctrl-contrast-rgb: 17, 35, 55;--gf-color-in-ctrl-darker: #F5F5F5;--gf-color-in-ctrl-lighter: #FFFFFF;--gf-color-in-ctrl-primary: #204ce5;--gf-color-in-ctrl-primary-rgb: 32, 76, 229;--gf-color-in-ctrl-primary-contrast: #fff;--gf-color-in-ctrl-primary-contrast-rgb: 255, 255, 255;--gf-color-in-ctrl-primary-darker: #001AB3;--gf-color-in-ctrl-primary-lighter: #527EFF;--gf-color-in-ctrl-light: rgba(17, 35, 55, 0.1);--gf-color-in-ctrl-light-rgb: 17, 35, 55;--gf-color-in-ctrl-light-darker: rgba(104, 110, 119, 0.35);--gf-color-in-ctrl-light-lighter: #F5F5F5;--gf-color-in-ctrl-dark: #585e6a;--gf-color-in-ctrl-dark-rgb: 88, 94, 106;--gf-color-in-ctrl-dark-darker: #112337;--gf-color-in-ctrl-dark-lighter: rgba(17, 35, 55, 0.65);--gf-radius: 3px;--gf-font-size-secondary: 14px;--gf-font-size-tertiary: 13px;--gf-icon-ctrl-number: url("data:image/svg+xml,%3Csvg width='8' height='14' viewBox='0 0 8 14' fill='none' xmlns='http://www.w3.org/2000/svg'%3E%3Cpath fill-rule='evenodd' clip-rule='evenodd' d='M4 0C4.26522 5.96046e-08 4.51957 0.105357 4.70711 0.292893L7.70711 3.29289C8.09763 3.68342 8.09763 4.31658 7.70711 4.70711C7.31658 5.09763 6.68342 5.09763 6.29289 4.70711L4 2.41421L1.70711 4.70711C1.31658 5.09763 0.683417 5.09763 0.292893 4.70711C-0.0976311 4.31658 -0.097631 3.68342 0.292893 3.29289L3.29289 0.292893C3.48043 0.105357 3.73478 0 4 0ZM0.292893 9.29289C0.683417 8.90237 1.31658 8.90237 1.70711 9.29289L4 11.5858L6.29289 9.29289C6.68342 8.90237 7.31658 8.90237 7.70711 9.29289C8.09763 9.68342 8.09763 10.3166 7.70711 10.7071L4.70711 13.7071C4.31658 14.0976 3.68342 14.0976 3.29289 13.7071L0.292893 10.7071C-0.0976311 10.3166 -0.0976311 9.68342 0.292893 9.29289Z' fill='rgba(17, 35, 55, 0.65)'/%3E%3C/svg%3E");--gf-icon-ctrl-select: url("data:image/svg+xml,%3Csvg width='10' height='6' viewBox='0 0 10 6' fill='none' xmlns='http://www.w3.org/2000/svg'%3E%3Cpath fill-rule='evenodd' clip-rule='evenodd' d='M0.292893 0.292893C0.683417 -0.097631 1.31658 -0.097631 1.70711 0.292893L5 3.58579L8.29289 0.292893C8.68342 -0.0976311 9.31658 -0.0976311 9.70711 0.292893C10.0976 0.683417 10.0976 1.31658 9.70711 1.70711L5.70711 5.70711C5.31658 6.09763 4.68342 6.09763 4.29289 5.70711L0.292893 1.70711C-0.0976311 1.31658 -0.0976311 0.683418 0.292893 0.292893Z' fill='rgba(17, 35, 55, 0.65)'/%3E%3C/svg%3E");--gf-icon-ctrl-search: url("data:image/svg+xml,%3Csvg width='640' height='640' xmlns='http://www.w3.org/2000/svg'%3E%3Cpath d='M256 128c-70.692 0-128 57.308-128 128 0 70.691 57.308 128 128 128 70.691 0 128-57.309 128-128 0-70.692-57.309-128-128-128zM64 256c0-106.039 85.961-192 192-192s192 85.961 192 192c0 41.466-13.146 79.863-35.498 111.248l154.125 154.125c12.496 12.496 12.496 32.758 0 45.254s-32.758 12.496-45.254 0L367.248 412.502C335.862 434.854 297.467 448 256 448c-106.039 0-192-85.962-192-192z' fill='rgba(17, 35, 55, 0.65)'/%3E%3C/svg%3E");--gf-label-space-y-secondary: var(--gf-label-space-y-md-secondary);--gf-ctrl-border-color: #686e77;--gf-ctrl-size: var(--gf-ctrl-size-md);--gf-ctrl-label-color-primary: #112337;--gf-ctrl-label-color-secondary: #112337;--gf-ctrl-choice-size: var(--gf-ctrl-choice-size-md);--gf-ctrl-checkbox-check-size: var(--gf-ctrl-checkbox-check-size-md);--gf-ctrl-radio-check-size: var(--gf-ctrl-radio-check-size-md);--gf-ctrl-btn-font-size: var(--gf-ctrl-btn-font-size-md);--gf-ctrl-btn-padding-x: var(--gf-ctrl-btn-padding-x-md);--gf-ctrl-btn-size: var(--gf-ctrl-btn-size-md);--gf-ctrl-btn-border-color-secondary: #686e77;--gf-ctrl-file-btn-bg-color-hover: #EBEBEB;--gf-field-img-choice-size: var(--gf-field-img-choice-size-md);--gf-field-img-choice-card-space: var(--gf-field-img-choice-card-space-md);--gf-field-img-choice-check-ind-size: var(--gf-field-img-choice-check-ind-size-md);--gf-field-img-choice-check-ind-icon-size: var(--gf-field-img-choice-check-ind-icon-size-md);--gf-field-pg-steps-number-color: rgba(17, 35, 55, 0.8);}</style>
                        <div class='gform_heading'>
                            <h2 class="gform_title">Approach to selecting antihyperglycemic agents</h2>
                            <p class='gform_description'><sup>1,13-23</sup></p>
                        </div><form method='post' enctype='multipart/form-data'  id='gform_42' class='hide-submit-button' action='/tool/type-2-diabetes-non-insulin-pharmacotherapy-2/' data-formid='42' novalidate>
                        <div class='gform-body gform_body'><div id='gform_fields_42' class='gform_fields top_label form_sublabel_below description_below validation_below'><div id="field_42_35" class="gfield gfield--type-html gfield--width-full input-type-html gfield_html gfield_html_formatted gfield_no_follows_desc field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible"  ><a href="https://link.cep.health/t2dmnoninhtml1" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Click here to view as image</a>
</ul></div><div id="field_42_1" class="gfield gfield--type-html input-type-html gfield_html gfield_html_formatted gfield_no_follows_desc field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible"  ><b>At diagnosis of type 2 diabetes</b> Start and support the ongoing maintenance of healthy lifestyle interventions (nutritional therapy, weight management, physical activity) +/- metformin
<ul>
  <li><b>Lifestyle interventions</b> have a greater potential for A1C lowering than any pharmacotherapy (nutrition A1C 1-2% and exercise A1C 0.5-0.7%)</li>
</ul></div><fieldset id="field_42_2" class="gfield gfield--type-radio gfield--type-choice gfield--width-full input-type-radio field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible"  ><legend class='gfield_label gform-field-label' >Select individualized A1C target</legend><div class='ginput_container ginput_container_radio'><div class='gfield_radio' id='input_42_2'>
			<div class='gchoice gchoice_42_2_0'>
					<input class='gfield-choice-input' name='input_2' type='radio' value='A1C less than 1.5% above target'  id='choice_42_2_0' onchange='gformToggleRadioOther( this )'    />
					<label for='choice_42_2_0' id='label_42_2_0' class='gform-field-label gform-field-label--type-inline'>A1C less than 1.5% above target</label>
			</div>
			<div class='gchoice gchoice_42_2_1'>
					<input class='gfield-choice-input' name='input_2' type='radio' value='A1C greater than or equal to 1.5% above target'  id='choice_42_2_1' onchange='gformToggleRadioOther( this )'    />
					<label for='choice_42_2_1' id='label_42_2_1' class='gform-field-label gform-field-label--type-inline'>A1C greater than or equal to 1.5% above target</label>
			</div>
			<div class='gchoice gchoice_42_2_2'>
					<input class='gfield-choice-input' name='input_2' type='radio' value='Symptomatic hyperglycemia &lt;br&gt; and/or metabolic decompensation*'  id='choice_42_2_2' onchange='gformToggleRadioOther( this )'    />
					<label for='choice_42_2_2' id='label_42_2_2' class='gform-field-label gform-field-label--type-inline'>Symptomatic hyperglycemia <br> and/or metabolic decompensation*</label>
			</div></div></div></fieldset><div id="field_42_20" class="gfield gfield--type-html gfield--width-full input-type-html gfield_html gfield_html_formatted gfield_no_follows_desc field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible"  ><span style="font-size:10.0pt">
* Severely elevated A1C and fasting blood glucose (e.g., A1C > 10% or blood glucose ≥ 16.7 mmol/L), even without symptomatic hyperglycemia and metabolic decompensation

<br>
Metabolic decompensation symptoms include: symptomatic hyperglycemia (e.g., polyuria, polydipsia, nocturia, blurred vision, fatigue, headache), marked hyperglycemia (blood glucose ≥16.7 mmol/L), unintentional weight loss, and ketosis

<br>See <a href="#a1c-targets-and-considerations-for-glycemic-control"> A1C targets and considerations for glycemic control</a></span></div><div id="field_42_8" class="gfield gfield--type-html gfield--width-full input-type-html gfield_html gfield_html_formatted gfield_no_follows_desc field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible has-conditional-logic"  data-field-class="has-conditional-logic" ><h6>A1C < 1.5% above target</h6>
Add metformin if lifestyle changes not expected to
reduce blood glucose levels by 3 months

<br>Reassess A1C in 3-6 months</br></div><div id="field_42_4" class="gfield gfield--type-html gfield--width-full input-type-html gfield_html gfield_html_formatted gfield_no_follows_desc field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible has-conditional-logic"  data-field-class="has-conditional-logic" ><h6>A1C ≥ 1.5% above target</h6>
Start metformin plus a second antihyperglycemic agent, and:
<ul>
<li>Check renal function before starting agent</li>
<li>Monitor for hypoglycemia when on multiple agents of different classes</li>
</div><div id="field_42_16" class="gfield gfield--type-html gfield--width-full input-type-html gfield_html gfield_html_formatted gfield_no_follows_desc field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible has-conditional-logic"  data-field-class="has-conditional-logic" ><h6>Symptomatic hyperglycemia and/or metabolic decompensation</h6>
<ul>
  <li>initiate insulin +/- metformin and titrate to achieving fasting blood glucose target (e.g., 4.0-7.0 mmol/L)</li>
  <li>See <a href="https://link.cep.health/t2dmnihtml3" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Type 2 diabetes: insulin therapy</a>
  </li>
</ul></div><fieldset id="field_42_14" class="gfield gfield--type-radio gfield--type-choice gfield--width-full input-type-radio field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible has-conditional-logic"  data-field-class="has-conditional-logic" ><legend class='gfield_label gform-field-label' >If patient is not at A1C target</legend><div class='ginput_container ginput_container_radio'><div class='gfield_radio' id='input_42_14'>
			<div class='gchoice gchoice_42_14_0'>
					<input class='gfield-choice-input' name='input_14' type='radio' value='at 3 months'  id='choice_42_14_0' onchange='gformToggleRadioOther( this )'    />
					<label for='choice_42_14_0' id='label_42_14_0' class='gform-field-label gform-field-label--type-inline'>at 3 months</label>
			</div>
			<div class='gchoice gchoice_42_14_1'>
					<input class='gfield-choice-input' name='input_14' type='radio' value='4-6 months or change in clinical status'  id='choice_42_14_1' onchange='gformToggleRadioOther( this )'    />
					<label for='choice_42_14_1' id='label_42_14_1' class='gform-field-label gform-field-label--type-inline'>4-6 months or change in clinical status</label>
			</div></div></div></fieldset><div id="field_42_11" class="gfield gfield--type-html gfield--width-full input-type-html gfield_html gfield_html_formatted gfield_no_follows_desc field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible has-conditional-logic"  data-field-class="has-conditional-logic" ><h6>Not at A1C target at 3 months</h6>
<ul>
<li>Start metformin (if not already started)</li>
<li> Adjust or advance therapy </li>
</ul></div><div id="field_42_15" class="gfield gfield--type-html gfield--width-full input-type-html gfield_html gfield_html_formatted gfield_no_follows_desc field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible has-conditional-logic"  data-field-class="has-conditional-logic" ><h6>Not at A1C target in 4-6 months or change in clinical status</h6> (e.g., changes in cardiovascular or renal status, presence of diabetes complications, side effects, and ability to take current medications).</div><div id="field_42_13" class="gfield gfield--type-html gfield--width-full input-type-html gfield_html gfield_html_formatted gfield_no_follows_desc field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible has-conditional-logic"  data-field-class="has-conditional-logic" ><b>Does patient have:</b>
<ul>
<li>Atherosclerotic cardiovascular disease OR</li>
<li>Chronic kidney disease OR</li>
<li>Heart failure OR</li>
<li>Age > 60 years with at least 2 cardiovascular risk factors: smoking (tobacco use), hypertension (untreated BP ≥ 140/95 or current antihypertensive therapy), dyslipidemia (use of lipid-modifying therapy or a documented untreated LDL > 3.4 mmol/L, or HDL-C < 1.0 mmol/L for men and < 1.3 mmol/L for women, or triglycerides > 2.3 mmol/L), central obesity (waist circumference of ≥ 80cm for females, ≥ 90-94cm for males)</li>

</div><fieldset id="field_42_12" class="gfield gfield--type-radio gfield--type-choice gfield--width-full input-type-radio field_sublabel_below gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible has-conditional-logic"  data-field-class="has-conditional-logic" ><legend class='gfield_label gform-field-label screen-reader-text' ></legend><div class='ginput_container ginput_container_radio'><div class='gfield_radio' id='input_42_12'>
			<div class='gchoice gchoice_42_12_0'>
					<input class='gfield-choice-input' name='input_12' type='radio' value='Yes'  id='choice_42_12_0' onchange='gformToggleRadioOther( this )'    />
					<label for='choice_42_12_0' id='label_42_12_0' class='gform-field-label gform-field-label--type-inline'>Yes</label>
			</div>
			<div class='gchoice gchoice_42_12_1'>
					<input class='gfield-choice-input' name='input_12' type='radio' value='No'  id='choice_42_12_1' onchange='gformToggleRadioOther( this )'    />
					<label for='choice_42_12_1' id='label_42_12_1' class='gform-field-label gform-field-label--type-inline'>No</label>
			</div></div></div></fieldset><div id="field_42_19" class="gfield gfield--type-html gfield--width-full input-type-html gfield_html gfield_html_formatted gfield_no_follows_desc field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible has-conditional-logic"  data-field-class="has-conditional-logic" ><h6>Add or substitute another antihyperglycemic agent based on shared decision-making factors (see <a href="#shared-decision-making"> Shared decision-making</a>)</h6><img decoding="async" class="" src="https://tools.cep.health/wp-content/uploads/2020/11/Management-table-1-shared-decision-making.png" alt="" width=100% height=auto /></div><div id="field_42_28" class="gfield gfield--type-html gfield--width-full input-type-html gfield_html gfield_html_formatted gfield_no_follows_desc field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible has-conditional-logic"  data-field-class="has-conditional-logic" ><h6>Add or substitute another antihyperglycemic agent with demonstrated cardiorenal benefits</h6><img decoding="async" class="" src="https://tools.cep.health/wp-content/uploads/2023/06/Cardiovascular-and-renal.png" alt="" width=100% height=auto /></div><fieldset id="field_42_23" class="gfield gfield--type-radio gfield--type-choice gfield--width-full input-type-radio field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible has-conditional-logic"  data-field-class="has-conditional-logic" ><legend class='gfield_label gform-field-label' >If patient is not at A1C target</legend><div class='ginput_container ginput_container_radio'><div class='gfield_radio' id='input_42_23'>
			<div class='gchoice gchoice_42_23_0'>
					<input class='gfield-choice-input' name='input_23' type='radio' value='at 3 months'  id='choice_42_23_0' onchange='gformToggleRadioOther( this )'    />
					<label for='choice_42_23_0' id='label_42_23_0' class='gform-field-label gform-field-label--type-inline'>at 3 months</label>
			</div>
			<div class='gchoice gchoice_42_23_1'>
					<input class='gfield-choice-input' name='input_23' type='radio' value='4-6 months or change in clinical status'  id='choice_42_23_1' onchange='gformToggleRadioOther( this )'    />
					<label for='choice_42_23_1' id='label_42_23_1' class='gform-field-label gform-field-label--type-inline'>4-6 months or change in clinical status</label>
			</div></div></div></fieldset><div id="field_42_21" class="gfield gfield--type-html gfield--width-full input-type-html gfield_html gfield_html_formatted gfield_no_follows_desc field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible has-conditional-logic"  data-field-class="has-conditional-logic" ><h6>Not at A1C target at 3 months</h6>
<ul>
<li>Start metformin (if not already started)</li>
<li> Adjust or advance therapy </li>
</ul></div><div id="field_42_24" class="gfield gfield--type-html gfield--width-full input-type-html gfield_html gfield_html_formatted gfield_no_follows_desc field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible has-conditional-logic"  data-field-class="has-conditional-logic" ><h6>Not at A1C target in 4-6 months or change in clinical status</h6> (e.g., changes in cardiovascular or renal status, presence of diabetes complications, side effects, and ability to take current medications).</div><div id="field_42_25" class="gfield gfield--type-html gfield--width-full input-type-html gfield_html gfield_html_formatted gfield_no_follows_desc field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible has-conditional-logic"  data-field-class="has-conditional-logic" ><b>Does patient have:</b>
<ul>
<li>Atherosclerotic cardiovascular disease OR</li>
<li>Chronic kidney disease OR</li>
<li>Heart failure OR</li>
<li>Age > 60 years with at least 2 cardiovascular risk factors: smoking (tobacco use), hypertension (untreated BP ≥ 140/95 or current antihypertensive therapy), dyslipidemia (use of lipid-modifying therapy or a documented untreated LDL > 3.4 mmol/L, or HDL-C < 1.0 mmol/L for men and < 1.3 mmol/L for women, or triglycerides > 2.3 mmol/L), central obesity (waist circumference of ≥ 80cm for females, ≥ 90-94cm for males)</li>

</div><fieldset id="field_42_26" class="gfield gfield--type-radio gfield--type-choice gfield--width-full input-type-radio field_sublabel_below gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible has-conditional-logic"  data-field-class="has-conditional-logic" ><legend class='gfield_label gform-field-label screen-reader-text' ></legend><div class='ginput_container ginput_container_radio'><div class='gfield_radio' id='input_42_26'>
			<div class='gchoice gchoice_42_26_0'>
					<input class='gfield-choice-input' name='input_26' type='radio' value='Yes'  id='choice_42_26_0' onchange='gformToggleRadioOther( this )'    />
					<label for='choice_42_26_0' id='label_42_26_0' class='gform-field-label gform-field-label--type-inline'>Yes</label>
			</div>
			<div class='gchoice gchoice_42_26_1'>
					<input class='gfield-choice-input' name='input_26' type='radio' value='No'  id='choice_42_26_1' onchange='gformToggleRadioOther( this )'    />
					<label for='choice_42_26_1' id='label_42_26_1' class='gform-field-label gform-field-label--type-inline'>No</label>
			</div></div></div></fieldset><div id="field_42_27" class="gfield gfield--type-html gfield--width-full input-type-html gfield_html gfield_html_formatted gfield_no_follows_desc field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible has-conditional-logic"  data-field-class="has-conditional-logic" ><h6>Add or substitute another antihyperglycemic agent based on shared decision-making factors (see <a href="#shared-decision-making"> Shared decision-making</a>)</h6><img decoding="async" class="" src="https://tools.cep.health/wp-content/uploads/2020/11/Management-table-1-shared-decision-making.png" alt="" width=100% height=auto /></div><div id="field_42_18" class="gfield gfield--type-html gfield--width-full input-type-html gfield_html gfield_html_formatted gfield_no_follows_desc field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible has-conditional-logic"  data-field-class="has-conditional-logic" ><h6>Add or substitute another antihyperglycemic agent with demonstrated cardiorenal benefits</h6><img decoding="async" class="" src="https://tools.cep.health/wp-content/uploads/2023/06/Cardiovascular-and-renal.png" alt="" width=100% height=auto /></div></div></div>
        <div class='gform-footer gform_footer top_label'> <input type='submit' id='gform_submit_button_42' class='gform_button button' onclick='gform.submission.handleButtonClick(this);' data-submission-type='submit' value='Submit'  /> 
            <input type='hidden' class='gform_hidden' name='gform_submission_method' data-js='gform_submission_method_42' value='postback' />
            <input type='hidden' class='gform_hidden' name='gform_theme' data-js='gform_theme_42' id='gform_theme_42' value='orbital' />
            <input type='hidden' class='gform_hidden' name='gform_style_settings' data-js='gform_style_settings_42' id='gform_style_settings_42' value='{&quot;inputPrimaryColor&quot;:&quot;#204ce5&quot;}' />
            <input type='hidden' class='gform_hidden' name='is_submit_42' value='1' />
            <input type='hidden' class='gform_hidden' name='gform_submit' value='42' />
            
            <input type='hidden' class='gform_hidden' name='gform_unique_id' value='' />
            <input type='hidden' class='gform_hidden' name='state_42' value='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' />
            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_target_page_number_42' id='gform_target_page_number_42' value='0' />
            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_source_page_number_42' id='gform_source_page_number_42' value='1' />
            <input type='hidden' name='gform_field_values' value='' />
            
        </div>
                        </form>
                        </div><script type="text/javascript">
/* <![CDATA[ */
 gform.initializeOnLoaded( function() {gformInitSpinner( 42, 'https://tools.cep.health/wp-content/themes/cep-tools/img/loader.svg', true );jQuery('#gform_ajax_frame_42').on('load',function(){var contents = jQuery(this).contents().find('*').html();var is_postback = contents.indexOf('GF_AJAX_POSTBACK') >= 0;if(!is_postback){return;}var form_content = jQuery(this).contents().find('#gform_wrapper_42');var is_confirmation = jQuery(this).contents().find('#gform_confirmation_wrapper_42').length > 0;var is_redirect = contents.indexOf('gformRedirect(){') >= 0;var is_form = form_content.length > 0 && ! is_redirect && ! is_confirmation;var mt = parseInt(jQuery('html').css('margin-top'), 10) + parseInt(jQuery('body').css('margin-top'), 10) + 100;if(is_form){form_content.find('form').css('opacity', 0);jQuery('#gform_wrapper_42').html(form_content.html());if(form_content.hasClass('gform_validation_error')){jQuery('#gform_wrapper_42').addClass('gform_validation_error');} else {jQuery('#gform_wrapper_42').removeClass('gform_validation_error');}setTimeout( function() { /* delay the scroll by 50 milliseconds to fix a bug in chrome */  }, 50 );if(window['gformInitDatepicker']) {gformInitDatepicker();}if(window['gformInitPriceFields']) {gformInitPriceFields();}var current_page = jQuery('#gform_source_page_number_42').val();gformInitSpinner( 42, 'https://tools.cep.health/wp-content/themes/cep-tools/img/loader.svg', true );jQuery(document).trigger('gform_page_loaded', [42, current_page]);window['gf_submitting_42'] = false;}else if(!is_redirect){var confirmation_content = jQuery(this).contents().find('.GF_AJAX_POSTBACK').html();if(!confirmation_content){confirmation_content = contents;}jQuery('#gform_wrapper_42').replaceWith(confirmation_content);jQuery(document).trigger('gform_confirmation_loaded', [42]);window['gf_submitting_42'] = false;wp.a11y.speak(jQuery('#gform_confirmation_message_42').text());}else{jQuery('#gform_42').append(contents);if(window['gformRedirect']) {gformRedirect();}}jQuery(document).trigger("gform_pre_post_render", [{ formId: "42", currentPage: "current_page", abort: function() { this.preventDefault(); } }]);        if (event && event.defaultPrevented) {                return;        }        const gformWrapperDiv = document.getElementById( "gform_wrapper_42" );        if ( gformWrapperDiv ) {            const visibilitySpan = document.createElement( "span" );            visibilitySpan.id = "gform_visibility_test_42";            gformWrapperDiv.insertAdjacentElement( "afterend", visibilitySpan );        }        const visibilityTestDiv = document.getElementById( "gform_visibility_test_42" );        let postRenderFired = false;        function triggerPostRender() {            if ( postRenderFired ) {                return;            }            postRenderFired = true;            gform.core.triggerPostRenderEvents( 42, current_page );            if ( visibilityTestDiv ) {                visibilityTestDiv.parentNode.removeChild( visibilityTestDiv );            }        }        function debounce( func, wait, immediate ) {            var timeout;            return function() {                var context = this, args = arguments;                var later = function() {                    timeout = null;                    if ( !immediate ) func.apply( context, args );                };                var callNow = immediate && !timeout;                clearTimeout( timeout );                timeout = setTimeout( later, wait );                if ( callNow ) func.apply( context, args );            };        }        const debouncedTriggerPostRender = debounce( function() {            triggerPostRender();        }, 200 );        if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) {            const observer = new MutationObserver( ( mutations ) => {                mutations.forEach( ( mutation ) => {                    if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) {                        debouncedTriggerPostRender();                        observer.disconnect();                    }                });            });            observer.observe( document.body, {                attributes: true,                childList: false,                subtree: true,                attributeFilter: [ 'style', 'class' ],            });        } else {            triggerPostRender();        }    } );} ); 
/* ]]> */
</script>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading" id="shared-decision-making">Shared decision-making</h3>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>Shared decision-making is an approach to clinical decision-making in which patients and providers jointly consider clinical factors and patient preferences to arrive at a mutually agreeable decision.<sup>24 </sup>Shared decision-making aims to bridge the information gap between patients and providers while prioritizing patient autonomy.<sup>24 </sup></p>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading">Engage patients in a discussion regarding which of the following factors are most important to them:<sup>25,26</sup></h6>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p><em>Use this information and a shared decision-making approach to support patients in deciding which diabetes therapy they would prefer.</em></p>
</div></article>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow" style="flex-basis:50%"><article class="block--table ">
<div class="container">
  <div class="table no-header inner-border-grey blue">

        
                    <div class="rows">

                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:5%;">
                                            <h6><img decoding="async" class="alignleft" src="https://tools.cep.health/wp-content/uploads/2020/11/money.png" alt="cost" /><strong> Affordability of therapy for 100 day supply</strong></h6>
<ul>
<li><strong> <span style="color: #008000;">Green</span></strong> = &lt; $100</li>
<li><strong> <span style="color: #f6be00;">Yellow </span></strong> = $100-$400</li>
<li><strong><span style="color: #ff6347;"> Red </span></strong> = &gt; $400</li>
</ul>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:5%;">
                                            <h6><img decoding="async" class="alignleft" src="https://tools.cep.health/wp-content/uploads/2020/11/IV.png" alt="IV" /><strong> Avoiding therapy that requires injections</strong></h6>
<ul>
<li><strong> <span style="color: #f6be00;">Yellow </span></strong> = weekly injection</li>
<li><strong><span style="color: #ff6347;"> Red </span></strong> = daily injection</li>
</ul>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:5%;">
                                            <h6><img decoding="async" class="alignleft" src="https://tools.cep.health/wp-content/uploads/2020/11/Glucose.png" alt="cost" /><strong> Avoiding therapy that increases risk of hypoglycemia</strong></h6>
<ul>
<li><strong><span style="color: #ff6347;"> Red </span></strong> = risk of hypoglycemia</li>
</ul>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:5%;">
                                            <h6><img decoding="async" class="alignleft" src="https://tools.cep.health/wp-content/uploads/2020/11/Heart.png" alt="Heart" /><strong> Therapy that provides cardiovascular benefits</strong></h6>
<ul>
<li><strong> <span style="color: #008000;">Green</span></strong> = cardiovascular benefit</li>
<li><strong><span style="color: #ff6347;"> Red </span></strong> = cardiovascular risk (e.g., worsening <span class="ILfuVd"><span class="hgKElc">MI</span></span> or heart failure)</li>
</ul>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                
            </div>
        
        
    </div>
</div>
</article></div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow" style="flex-basis:50%"><article class="block--table ">
<div class="container">
  <div class="table no-header inner-border-grey blue">

        
                    <div class="rows">

                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:5%;">
                                            <h6><img decoding="async" class="alignleft" src="https://tools.cep.health/wp-content/uploads/2020/11/time.png" alt="cost" /><strong> Therapy that fits with daily routine</strong></h6>
<ul>
<li><strong> <span style="color: #008000;">Green</span></strong> = once daily or less administration</li>
<li><strong> <span style="color: #f6be00;">Yellow </span></strong> = ranges from once daily to 3+ daily</li>
<li><strong><span style="color: #ff6347;"> Red </span></strong> = 3+ administration per day, inconvenient</li>
</ul>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:5%;">
                                            <h6><img decoding="async" class="alignleft" src="https://tools.cep.health/wp-content/uploads/2020/11/GI.png" alt="cost" /> <strong>Avoiding therapy that has gastrointestinal side effects</strong></h6>
<ul>
<li><strong><span style="color: #ff6347;"> Red </span></strong> = gastrointestinal side effects are common</li>
</ul>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:5%;">
                                            <h6><img decoding="async" class="alignleft" src="https://tools.cep.health/wp-content/uploads/2020/11/weight.png" alt="weight" /><strong> Therapy that impacts weight change<br />
</strong></h6>
<ul>
<li><strong> <span style="color: #008000;">Green</span></strong> = decreases weight</li>
<li><strong><span style="color: #ff6347;"> Red </span></strong> = increases weight</li>
</ul>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:5%;">
                                            <h6><img decoding="async" class="alignleft" src="https://tools.cep.health/wp-content/uploads/2020/11/Lung.png" alt="Lung" /><strong> Therapy that provides kidney protection</strong></h6>
<ul>
<li><strong> <span style="color: #008000;">Green</span></strong> = provides kidney protection</li>
<li><strong><span style="color: #ff6347;"> Red </span></strong> = may cause acute renal injury</li>
</ul>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                
            </div>
        
        
    </div>
</div>
</article></div>
</div>
						</div>
					</div>
				</section>
							<section class="main-section" id="non-insulin-pharmacotherapy-options" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Non-insulin pharmacotherapy options								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading" id="non-insulin">Non-insulin pharmacotherapy</h3>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Eye.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <h6 style="text-align: left;"><a href="https://link.cep.health/t2dmnoninhtml30" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">View in table format</a></h6>
          </div>
        </div>

      </div>
</article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>See <a href="#definitions">definitions of acronyms</a> used throughout the following pharmacotherapy cards</p>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h4 class="wp-block-heading">First line options<sup>13,29-32</sup></h4>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead">Biguanides </span>
                    <h6><u>Metformin HCL </u>/ Glucophage® <br><span style="font-size:9.0pt">Agent with evidence-based outcome benefits</span><br><img loading="lazy" decoding="async" src="https://tools.cep.health/wp-content/uploads/2023/08/icon_yellowclock.png" alt="" width="100" height="20"></h6>
                    <p><span style="font-size: 13.5px;">500mg tab, 850mg tab and generic available</span></p>
<p><span style="font-size: 13.5px;"><strong>Coverage</strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">ODB ✓: 500mg tab</span></li>
<li><span style="font-size: 13.5px;">ODB X: 850mg tab</span></li>
<li><span style="font-size: 13.5px;">NIHB✓<br />
</span></li>
</ul>
<p><span style="font-size: 13.5px;"><strong>A1C reduction (%):</strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">1.0</span></li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>Initial: 250–500mg po daily cc</li>
<li>Usual: 1000mg po bid cc OR 1700mg cc am and 850mg cc pm</li>
<li>Max: 2550mg daily OR 850mg tid</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>eGFR 30-45mL/min (≤1000mg daily)</li>
<li>eGFR &lt;30mL/min (avoid*)<br />
<sub>*Sometimes used at low dose when eGFR between 15-30 mL/min in renally stable patients</sub></li>
</ul>
<p><span style="font-size: 13.5px;"><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">Generic: $20 (1g bid) to $80 (850mg tid)</span></li>
<li><span style="font-size: 13.5px;">Trade: $140</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="Sf3ozc">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="Sf3ozc">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Metformin HCL / Glucophage®</h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Reduced MI in overweight (&gt;120% IBW) patients</li>
<li>Reduced all-cause mortality</li>
<li>Reduced insulin requirements</li>
</ul>
<h6>Weight</h6>
<ul>
<li>Loss of up to 2.9kg in 5 years</li>
</ul>
<h6>Harms, hypoglycemic risk<sup> </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>GI intolerance</li>
<li>Vitamin B12 deficiency</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>Titrate up every 1–2 weeks to avoid GI AE</li>
<li>Take with largest meal to minimize GI AE</li>
<li>85% of max glucose lowering seen at 1500 mg daily</li>
<li>Fewer GI side effects with ER formulation</li>
<li>Monitor: hemoglobin and vitamin B12 deficiency (annually), SCr (baseline and periodically)</li>
<li>On <a href="https://link.cep.health/t2dm7" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">SADMANS</a> list</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Biguanides</span>
                    <h6><u>Metformin HCL</u> / Glumetza® <br><span style="font-size:9.0pt"><b>Agent with evidence-based outcome benefits</b></span><br><img loading="lazy" decoding="async" src="https://tools.cep.health/wp-content/uploads/2021/11/pharmoption1.png" alt="" width="100" height="20"></h6>
                    <p><span style="font-size: 13.5px;">500 mg extended release tab, 1000mg extended release tab and generic available</span></p>
<p><span style="font-size: 13.5px;"><strong>Coverage: </strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">ODB X</span></li>
<li><span style="font-size: 13.5px;">NIHB X</span></li>
</ul>
<p><span style="font-size: 13.5px;"><strong>A1C reduction (%):</strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">1.0</span></li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>Initial: 250–500mg po daily cc</li>
<li>Usual: 1000–2000mg po cc pm</li>
<li>Max: 2500mg daily</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>eGFR 30-45mL/min (≤1000mg daily)</li>
<li>eGFR &lt;30mL/min (avoid*)<br />
<sub>*Sometimes used at low dose when eGFR between 15-30 mL/min in renally stable patients</sub></li>
</ul>
<p><span style="font-size: 13.5px;"><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">Generic: $120 (1g/d) to $235 (2g/d)</span></li>
<li><span style="font-size: 13.5px;">Trade: $300 (2g/d)</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="u48FRb">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="u48FRb">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Metformin HCL / Glumetza®</h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Reduced MI in overweight (&gt;120% IBW) patients</li>
<li>Reduced all-cause mortality</li>
<li>Reduced insulin requirements</li>
</ul>
<h6>Weight</h6>
<ul>
<li>Loss of up to 2.9kg in 5 years</li>
</ul>
<h6>Harms, hypoglycemic risk<sup> </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>GI intolerance</li>
<li>Vitamin B12 deficiency</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>Titrate up every 1–2 weeks to avoid GI AE</li>
<li>Take with largest meal to minimize GI AE</li>
<li>85% of max glucose lowering seen at 1500 mg daily</li>
<li>Fewer GI side effects with ER formulation</li>
<li>Monitor: hemoglobin and vitamin B12 deficiency (annually), SCr (baseline and periodically)</li>
<li>On <a href="https://link.cep.health/t2dmnihtml4" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">SADMANS</a> list</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h4 class="wp-block-heading">Second line options<sup>1,13,15-19,29,30,32,33-37,38</sup></h4>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Yellow-Notice.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <ul>
<li><strong>Avoid combining <span class="subhead">Dipeptidyl peptidase-4 inhibitor (DPP4i)</span> with <span class="subhead">Glucagon-like peptide-1 receptor agonists (GLP1-RA)</span>.</strong></li>
<li><strong>Insulin secretagogues – sulfonylureas: Risk of hypoglycemia: gliclazide &lt; glimepiride &lt; glyburide</strong></li>
</ul>
          </div>
        </div>

      </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading">Alpha-glucosidase inhibitor</h6>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Acarbose / Glucobay® <br><img loading="lazy" decoding="async" style="font-size: 1.5rem;" src="https://tools.cep.health/wp-content/uploads/2021/11/pharmoption2.png" width="70" height="20"/></h6>
                    <p><span style="font-size: 13.5px;">50mg tab, 100mg tab and generic available<br />
</span></p>
<p><span style="font-size: 13.5px;"><strong>Coverage</strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">ODB✓ (<a href="https://link.cep.health/t2dmnihtml5" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">LU 175, 176</a>) </span></li>
<li><span style="font-size: 13.5px;">NIHB ✓ </span></li>
</ul>
<p><span style="font-size: 13.5px;"><strong>A1C reduction (%):</strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">0.7-0.8</span></li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>Initial: 25mg po daily cc</li>
<li>Usual: 50–100mg po tid cc</li>
<li>Max: 100mg po tid cc</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>eGFR&lt;25-30mL/min (contraindication)</li>
</ul>
<p><span style="font-size: 13.5px;"><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">Generic: $74 to $100</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="YYpIJ2">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="YYpIJ2">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Acarbose / Glucobay®</h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Improved postprandial control</li>
</ul>
<h6>Weight</h6>
<ul>
<li>Neutral effect on weight</li>
</ul>
<h6>Harms, hypoglycemic risk<sup> </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>GI intolerance, flatulence, diarrhea</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>Titrate up every 1–2 weeks until 50 mg tid to avoid GI AE; then every 4–8 weeks</li>
<li>Max effect may take weeks</li>
<li>Take with first bite of meal</li>
<li>Monitor: SCr and LFTs (baseline and periodically)</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading">DPP4i</h6>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead">DPP4i</span>
                    <h6>Alogliptin / Nesina® <br><img loading="lazy" decoding="async" style="font-size: 1.5rem;" src="https://tools.cep.health/wp-content/uploads/2021/11/pharmoption3.png" width="45" height="20"/></h6>
                    <p><span style="font-size: 13.5px;"><strong>NOT on Ontario drug formulary </strong></span></p>
<p><span style="font-size: 13.5px;"> </span><span style="font-size: 13.5px;">6.25mg tab, 12.5mg tab and 25mg tab</span></p>
<p><span style="font-size: 13.5px;"><strong>Coverage: </strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">ODB X</span></li>
<li><span style="font-size: 13.5px;"> NIHB X<br />
</span></li>
</ul>
<p><span style="font-size: 13.5px;"><strong>A1C reduction (%):</strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">0.5–0.7</span></li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>25mg po daily</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>eGFR 30-50mL/min (12.5mg po daily)</li>
<li>eGFR &lt;30mL/min (6.25mg po daily)</li>
</ul>
<p><span style="font-size: 13.5px;"><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">Trade: $265</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="VueTmI">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="VueTmI">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Alogliptin / Nesina®</h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Improved postprandial control</li>
<li>Well tolerated option in older adults</li>
<li>Neutral effect on CVD outcomes</li>
</ul>
<h6>Weight</h6>
<ul>
<li>Neutral effect on weight</li>
</ul>
<h6>Harms, hypoglycemic risk<sup>  </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>Pancreatitis (rare), severe joint pain (rare)</li>
<li>Alogliptin: possible worsening of HF in patients with acute coronary syndrome without a history of HF</li>
<li>Saxagliptin: HF</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>Monitor: SCr (baseline and periodically), LFTs (baseline, especially for alogliptin)</li>
<li>Alogliptin: may increase LFTs</li>
<li>Linagliptin: no dosage adjustment in renal impairment</li>
<li>Saxagliptin: avoid in HF</li>
</ul>
<p>&nbsp;</p>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">DPP4i</span>
                    <h6>Linagliptin / Trajenta® <br><img loading="lazy" decoding="async" style="font-size: 1.5rem;" src="https://tools.cep.health/wp-content/uploads/2021/11/pharmoption3.png" width="45" height="20"/></h6>
                    <p><span style="font-size: 13.5px;">5mg tab</span></p>
<p><span style="font-size: 13.5px;"><strong>Coverage: </strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">ODB ✓ </span></li>
<li><span style="font-size: 13.5px;">NIHB✓<br />
</span></li>
</ul>
<p><span style="font-size: 13.5px;"><strong>A1C reduction (%):</strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">0.5–0.7</span></li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>5mg po daily</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>eGFR &lt;15mL/min (use with caution). No dosage adjustment.</li>
</ul>
<p><span style="font-size: 13.5px;"><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">Trade: $297</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="X2Mbdx">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="X2Mbdx">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Linagliptin / Trajenta®</h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Improved postprandial control</li>
<li>Well tolerated option in older adults</li>
<li>Neutral effect on CVD outcomes</li>
</ul>
<h6>Weight</h6>
<ul>
<li>Neutral effect on weight</li>
</ul>
<h6>Harms, hypoglycemic risk<sup>  </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>Pancreatitis (rare), severe joint pain (rare)</li>
<li>Alogliptin: possible worsening of HF in patients with acute coronary syndrome without a history of HF</li>
<li>Saxagliptin: HF</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>Monitor: SCr (baseline and periodically), LFTs (baseline, especially for alogliptin)</li>
<li>Alogliptin: may increase LFTs</li>
<li>Linagliptin: no dosage adjustment in renal impairment</li>
<li>Saxagliptin: avoid in HF</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">DPP4i</span>
                    <h6>Saxagliptin / Onglyza® <br><img loading="lazy" decoding="async" style="font-size: 1.5rem;" src="https://tools.cep.health/wp-content/uploads/2021/11/pharmoption3.png" width="45" height="20"/></h6>
                    <p><span style="font-size: 13.5px;">2.5mg tab and 5mg tab</span></p>
<p><span style="font-size: 13.5px;"><strong>Coverage: </strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">ODB ✓ </span></li>
<li><span style="font-size: 13.5px;">NIHB ✓<br />
</span></li>
</ul>
<p><span style="font-size: 13.5px;"><strong>A1C reduction (%):</strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">0.5–0.7</span></li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>5mg po daily</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>eGFR &lt;50mL/min (2.5mg po daily)</li>
<li>eGFR &lt;15mL/min (use alternative agent)</li>
</ul>
<p><span style="font-size: 13.5px;"><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">Trade: $337</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="Cy7oOz">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="Cy7oOz">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Saxagliptin / Onglyza® </h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Improved postprandial control</li>
<li>Well tolerated option in older adults</li>
<li>Neutral effect on CVD outcomes</li>
</ul>
<h6>Weight</h6>
<ul>
<li>Neutral effect on weight</li>
</ul>
<h6>Harms, hypoglycemic risk<sup>  </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>Pancreatitis (rare), severe joint pain (rare)</li>
<li>Alogliptin: possible worsening of HF in patients with acute coronary syndrome without a history of HF</li>
<li>Saxagliptin: HF</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>Monitor: SCr (baseline and periodically), LFTs (baseline, especially for alogliptin)</li>
<li>Alogliptin: may increase LFTs</li>
<li>Linagliptin: no dosage adjustment in renal impairment</li>
<li>Saxagliptin: avoid in HF</li>
</ul>
<p>&nbsp;</p>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">DPP4i</span>
                    <h6>Sitagliptin / Januvia® <br><img loading="lazy" decoding="async" style="font-size: 1.5rem;" src="https://tools.cep.health/wp-content/uploads/2021/11/pharmoption3.png" width="45" height="20"/></h6>
                    <p><span style="font-size: 13.5px;">25mg tab, 50mg tab and 100mg tab</span></p>
<p><span style="font-size: 13.5px;"><strong>Coverage: </strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">ODB ✓ </span></li>
<li><span style="font-size: 13.5px;">NIHB ✓ LU </span><span style="font-size: 9.0pt;">(for patients who did not achieve glycemic control or who demonstrated intolerance to an adequate trial of metformin and a sulfonylurea)</span></li>
</ul>
<p><span style="font-size: 13.5px;"><strong>A1C reduction (%):</strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">0.5–0.7</span></li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>100mg po daily</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>eGFR 30-49mL/min (50mg po daily)</li>
<li>eGFR &lt;30mL/min, hemodialysis, peritoneal dialysis, chronic kidney disease (25mg po daily)</li>
</ul>
<p><span style="font-size: 13.5px;"><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">Trade: $99</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="bFHPzu">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="bFHPzu">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Sitagliptin / Januvia®</h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Improved postprandial control</li>
<li>Well tolerated option in older adults</li>
<li>Neutral effect on CVD outcomes</li>
</ul>
<h6>Weight</h6>
<ul>
<li>Neutral effect on weight</li>
</ul>
<h6>Harms, hypoglycemic risk<sup>  </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>Pancreatitis (rare), severe joint pain (rare)</li>
<li>Alogliptin: possible worsening of HF in patients with acute coronary syndrome without a history of HF</li>
<li>Saxagliptin: HF</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>Monitor: SCr (baseline and periodically), LFTs (baseline, especially for alogliptin)</li>
<li>Alogliptin: may increase LFTs</li>
<li>Linagliptin: no dosage adjustment in renal impairment</li>
<li>Saxagliptin: avoid in HF</li>
</ul>
<p>&nbsp;</p>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading">GIP and&nbsp;GLP1-RA</h6>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Tirzepatide (Mounjaro) <br><img loading="lazy" decoding="async" style="font-size: 1.5rem;" src="https://tools.cep.health/wp-content/uploads/2023/08/CEP_Type2DiabetesNonInsulin_icons_aug2.png" width="60" height="18"/></h6>
                    <p><span style="font-size: 13.5px;">Pre-filled pen 4 (single dose pen): Solution, 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, 15 mg/0.5 mL</span></p>
<p><span style="font-size: 13.5px;"><strong>Coverage: </strong> </span></p>
<ul>
<li>Currently unavailable for ordering. Awaiting supply.</li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>Initial: 2.5 mg subcut once weekly x 4 weeks</li>
<li>Usual: 5 mg subcut once weekly<br />
If additional glycemic control is needed, increase the dosage in increments of 2.5 mg after no less than 4 weeks on the current dose, as tolerated</li>
<li>Max: 15 mg subcut once weekly</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>No dosage adjustment is required in renal impairment. Tirzepatide is not recommended in end stage renal impairment</li>
</ul>
<p><span style="font-size: 13.5px;"><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></span></p>
<ul>
<li>Currently unavailable for ordering. Awaiting supply.</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="7nfCTk">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="7nfCTk">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Tirzepatide (Mounjaro)</h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Under investigation</li>
</ul>
<h6>Weight</h6>
<ul>
<li>Loss up to 11.3 kg over 26 weeks</li>
</ul>
<h6>Harms, hypoglycemic risk<sup>  </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>Subcut injection irritation  <img loading="lazy" decoding="async" class="" src="https://tools.cep.health/wp-content/uploads/2021/11/injection-red.png" alt="" width="19" height="19" /></li>
<li>GI side effects, acute pancreatitis / gallstone disease (rare)</li>
<li>Contraindicated with personal / family hx of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2</li>
<li>Increased risk of hypoglycemia when used in combination with SU or insulin treatment. Consider SU or insulin dosage reduction of 10-20%</li>
<li>
<p class="p1">Increased risk of biliary disease, particularly when it is used at higher doses, longer durations, or for weight loss (off-label)</p>
</li>
<li>
<p class="p1">Delays gastric emptying; consider holding for 3 weeks before surgery</p>
</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>Monitor: SCr, weight, and GI tolerability (baseline and periodically)</li>
<li>Avoid combining DPP4i with GLP1-RA</li>
<li>Caution weight loss in frail older adults</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading">GLP1-RA</h6>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead">GLP1-RA – longer acting </span>
                    <h6>Dulaglutide / Trulicity® <br><span style="font-size:9.0pt">Agent with evidence-based outcome benefits</span><br><img loading="lazy" decoding="async" style="font-size: 1.5rem;" src="https://tools.cep.health/wp-content/uploads/2021/11/pharmoption5-1.png" width="130" height="20"/></h6>
                    <p><span style="font-size: 13.5px;"><strong>NOT on Ontario drug formulary </strong></span></p>
<p><span style="font-size: 13.5px;">Pre-filled pen (single use) 0.75mg/0.5ml, 1.5mg/0.5ml<br />
</span></p>
<p><span style="font-size: 13.5px;"><strong>Coverage: </strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">ODB X</span></li>
<li><span style="font-size: 13.5px;">NIHB X<br />
</span></li>
</ul>
<p><span style="font-size: 13.5px;"><strong>A1C reduction (%):</strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">0.6-1.4</span></li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>Initial: 0.75mg subcut once weekly</li>
<li>Usual: After ≥ 4 weeks at 1.5mg subcut once weekly</li>
<li>Max: After ≥ 4 weeks at 1.5mg subcut once weekly consider increase to 3 mg subcut once weekly for additional glycemic control</li>
<li>After ≥ 4 weeks at 3 mg subcut once weekly consider 4.5 mg subcut once weekly for additional glycemic control</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>eGFR &lt;15mL/min (caution)</li>
</ul>
<p><span style="font-size: 13.5px;"><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></span></p>
<ul>
<li><span style="font-size: 13.5px;">Trade: $720 (12 weeks)</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="bMHmB8">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="bMHmB8">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Dulaglutide / Trulicity® </h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Reduced MACE in patients with clinical CVD or high risk for CVD</li>
<li>Reduced insulin requirements</li>
</ul>
<h6>Weight</h6>
<ul>
<li>Loss of 1.6-3kg</li>
</ul>
<h6>Harms, hypoglycemic risk<sup>  </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>Subcut injection irritation  <img loading="lazy" decoding="async" class="" src="https://tools.cep.health/wp-content/uploads/2021/11/injection-red.png" alt="" width="19" height="19" /></li>
<li>GI side effects: nausea, vomiting, diarrhea, abdominal pain, dyspepsia and constipation
<ul>
<li>Less GI side effects with weekly GLP1-RA vs daily</li>
<li>More GI side effects during initiation and titration</li>
<li>Caution recommended in patients with gastroparesis (not studied)</li>
</ul>
</li>
<li>Increase risk of hypoglycemia when administered with sulfonylurea or insulin</li>
<li>Increase risk of hypogylcemia with oral semaglutide</li>
<li>Contraindicated in pregnancy and breastfeeding. Women of child-bearing potential should be advised to use contraception with taking GLP1s</li>
<li>Contraindicated in patients with personal/family hx of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (C-cell/thyroid tumours in animals)</li>
<li>Rare side effects: increased heart rate, pancreatitis, cholecystitis, acute kidney injury, retinopathy, pancreatic cancer</li>
<li>Increased risk of biliary disease, particularly when it is used at higher doses, longer durations, or for weight loss (off-label)</li>
<li>Delays gastric emptying; consider holding for 3 weeks before surgery</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>Monitor: SCr, weight, HR and GI tolerability (baseline and periodically)</li>
<li>Titrate up to 1.5 mg subcut once weekly after 4-8 to minimize AE</li>
<li>Caution weight loss in frail older adults</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">GLP1-RA – longer acting </span>
                    <h6>Liraglutide / Victoza® <br><span style="font-size:9.0pt">Agent with evidence-based outcome benefits</span><br><img loading="lazy" decoding="async" style="font-size: 1.5rem;" src="https://tools.cep.health/wp-content/uploads/2021/11/pharmoption5-1.png" width="130" height="20"/></h6>
                    <p><strong>NOT on Ontario drug formulary </strong></p>
<p>Pre-filled pen (multiuse): 6mg/mL; 3mL Pk</p>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB X</li>
<li>NIHB X</li>
</ul>
<p><strong>A1C reduction (%):</strong></p>
<ul>
<li>0.6-1.4</li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>Initial: 0.6mg subcut daily</li>
<li>Usual: After ≥1 week, increase to 1.2mg subcut daily x 1 week, then 1.8mg subcut daily</li>
<li>Max: 1.8mg/d</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>eGFR &lt;30mL/min (caution) no dosage adjustment</li>
<li>eGFR &lt;15 mL/min (contraindicated)</li>
</ul>
<p><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></p>
<ul>
<li>Trade : $1095 (1.8mg subcut daily x 100 days)</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="fPA8xV">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="fPA8xV">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Liraglutide / Victoza®</h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Reduced CV death in patients with ASCVD</li>
<li>Reduced MACE in patients with ASCVD or high risk for CVD<u><br />
</u></li>
<li>Reduced insulin requirements</li>
</ul>
<h6>Weight</h6>
<ul>
<li>Loss of 1.6-3kg</li>
</ul>
<h6>Harms, hypoglycemic risk<sup>  </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>Subcut injection irritation  <img loading="lazy" decoding="async" class="" src="https://tools.cep.health/wp-content/uploads/2021/11/injection-red.png" alt="" width="19" height="19" /></li>
<li>GI side effects: nausea, vomiting, diarrhea, abdominal pain, dyspepsia and constipation
<ul>
<li>Less GI side effects with weekly GLP1-RA vs daily</li>
<li>More GI side effects during initiation and titration</li>
<li>Caution recommended in patients with gastroparesis (not studied)</li>
</ul>
</li>
<li>Increase risk of hypoglycemia when administered with sulfonylurea or insulin</li>
<li>Increase risk of hypogylcemia with oral semaglutide</li>
<li>Contraindicated in pregnancy and breastfeeding. Women of child-bearing potential should be advised to use contraception with taking GLP1s</li>
<li>Contraindicated in patients with personal/family hx of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (C-cell/thyroid tumours in animals)</li>
<li>Rare side effects: increased heart rate, pancreatitis, cholecystitis, acute kidney injury, retinopathy, pancreatic cancer</li>
<li>Increased risk of biliary disease, particularly when it is used at higher doses, longer durations, or for weight loss (off-label)</li>
<li>Delays gastric emptying; consider holding for 3 days before surgery</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>Titrate up after 1 week to reduce GI AE (see usual dose)</li>
<li>If &gt;3 missed doses, restart at 0.6mg daily and titrate</li>
<li>Monitor: SCr, weight, HR and GI tolerability (baseline and periodically)</li>
<li>Caution weight loss in frail older adults</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">GLP1-RA – longer acting </span>
                    <h6>Semaglutide / Ozempic® <br><span style="font-size:9.0pt">Agent with evidence-based outcome benefits</span><br><img loading="lazy" decoding="async" style="font-size: 1.5rem;" src="https://tools.cep.health/wp-content/uploads/2021/11/pharmoption5-1.png" width="130" height="20"/></h6>
                    <p>Pre-filled pen (multiuse): 1.34mg/mL; 1.5mL, 3mL Pk</p>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>A1C reduction (%):</strong></p>
<ul>
<li>1.5-2.0</li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>Initial: 0.25mg subcut once weekly</li>
<li>Usual: After ≥4 weeks increase to 0.5mg subcut once weekly x 4 weeks, then titrate up to 1mg subcut weekly as tolerated</li>
<li>Max: 1-2 mg subcut once weekly</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>eGRF &lt;15 mL/min (contraindicated)</li>
<li>eGFR &lt;30mL/min (caution) no dosage adjustment</li>
</ul>
<p><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></p>
<ul>
<li>Trade : $390-$772</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="9JoJWe">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="9JoJWe">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Semaglutide / Ozempic®</h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Reduced MACE in patients with ASCVD or high for CVD</li>
</ul>
<h6>Weight</h6>
<ul>
<li>Loss of up to 4kg in 2 years</li>
</ul>
<h6>Harms, hypoglycemic risk<sup>  </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>Subcut injection irritation  <img loading="lazy" decoding="async" class="" src="https://tools.cep.health/wp-content/uploads/2021/11/injection-red.png" alt="" width="19" height="19" /></li>
<li>GI side effects: nausea, vomiting, diarrhea, abdominal pain, dyspepsia and constipation
<ul>
<li>Less GI side effects with weekly GLP1-RA vs daily</li>
<li>More GI side effects during initiation and titration</li>
<li>Caution recommended in patients with gastroparesis (not studied)</li>
</ul>
</li>
<li>Increase risk of hypoglycemia when administered with sulfonylurea or insulin</li>
<li>Increase risk of hypogylcemia with oral semaglutide</li>
<li>Contraindicated in pregnancy and breastfeeding. Women of child-bearing potential should be advised to use contraception with taking GLP1s</li>
<li>Contraindicated in patients with personal/family hx of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (C-cell/thyroid tumours in animals)</li>
<li>Rare side effects: increased heart rate, pancreatitis, cholecystitis, acute kidney injury, retinopathy, pancreatic cancer</li>
<li>Increased risk of biliary disease, particularly when it is used at higher doses, longer durations, or for weight loss (off-label)</li>
<li>Delays gastric emptying; consider holding for 3 weeks before surgery</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>Titrate after ≥ 4 weeks to minimize GI AE (see usual dose)</li>
<li>Monitor: SCr, weight, HR and GI tolerability (baseline and periodically)</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">GLP1-RA – longer acting </span>
                    <h6>Semaglutide / Rybelsus® <br><span style="font-size:9.0pt">Agent with evidence-based outcome benefits</span><br><img loading="lazy" decoding="async" style="font-size: 1.5rem;" src="https://tools.cep.health/wp-content/uploads/2023/06/CEP_Type2DiabetesNonInsulin_June21_icons.png" width="130" height="20"/></h6>
                    <p>3mg tab, 7mg tab and 14mg tab</p>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB ✓ (LU <a href="https://link.cep.health/t2dmnihtml27" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">662</a>, <a href="https://link.cep.health/t2dmnihtml28" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">663</a>, <a href="https://link.cep.health/t2dmnihtml29" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">664</a>)</li>
<li>NIHB X</li>
</ul>
<p><strong>A1C reduction (%):</strong></p>
<ul>
<li>1.1</li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>Initial: 3mg po daily 30 mins ac</li>
<li>Usual: After 30 days increase to 7mg daily 30 mins ac</li>
<li>Max: 14mg daily</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>Not studied in eGFR &lt; 30mL/min (contraindicated)</li>
</ul>
<p><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></p>
<ul>
<li>Trade : $818</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="9DxRaK">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="9DxRaK">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Semaglutide / Rybelsus®</h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Neutral effect on CVD outcomes or MACE</li>
<li>Reduced insulin requirements</li>
</ul>
<h6>Weight</h6>
<ul>
<li>Loss of up to 5kg in 1 years</li>
</ul>
<h6>Harms, hypoglycemic risk<sup>  </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>GI side effects: nausea, vomiting, diarrhea, abdominal pain, dyspepsia and constipation
<ul>
<li>More GI side effects during initiation and titration</li>
<li>Caution recommended in patients with gastroparesis (not studied)</li>
</ul>
</li>
<li>Increase risk of hypoglycemia when administered with sulfonylurea or insulin</li>
<li>Increase risk of hypogylcemia with oral semaglutide</li>
<li>Contraindicated in pregnancy and breastfeeding. Women of child-bearing potential should be advised to use contraception with taking GLP1s</li>
<li>Contraindicated in patients with personal/family hx of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (C-cell/thyroid tumours in animals)</li>
<li>Rare side effects: increased heart rate, pancreatitis, cholecystitis, acute kidney injury, retinopathy, pancreatic cancer</li>
<li>Increased risk of biliary disease, particularly when it is used at higher doses, longer durations, or for weight loss (off-label)</li>
<li>Delays gastric emptying; consider holding for 3 weeks before surgery</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>Increase dose ≥ 30 days apart to reduce GI AE (see usual dose)</li>
<li>To be taken with 120mL of water</li>
<li>Monitor: SCr, HR, hypoglycemia, weight and GI tolerability (baseline and periodically)</li>
<li>Caution weight loss in frail older adults</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading">Insulin secretagogues</h6>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead">Insulin secretagogues – meglitinides </span>
                    <h6>Repaglinide / Gluconorm® <br><img loading="lazy" decoding="async" src="https://tools.cep.health/wp-content/uploads/2023/08/icon_pg5_redclock.png" alt="" class="wp-image-44788" width="122" height="20"/></h6>
                    <p>0.5mg tab, 1mg tab, 2mg tab and generic available</p>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB X <a href="https://link.cep.health/t2dmnihtml6" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">EAP</a></li>
<li>NIHB ✓</li>
</ul>
<p><strong>A1C reduction (%):</strong></p>
<ul>
<li>0.7-1.1</li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>Initial: A1C &lt;8% 0.5mg po tid ac, A1C ≥8% 1-2mg po tid ac</li>
<li>Usual: 1-4mg po bid-qid ac</li>
<li>Max: 16mg daily</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>eGFR &lt;30mL/min (caution)</li>
</ul>
<p><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></p>
<ul>
<li>Generic: $79-$167</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="CFRC8b">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="CFRC8b">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Repaglinide / Gluconorm®</h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Neutral CVD events and mortality</li>
<li>Postprandial glycemia is especially reduced by meglitinides</li>
<li>Meglitinides good for patients who skip meals<em><br />
</em></li>
</ul>
<h6>Weight</h6>
<ul>
<li>Gain of 1.4-3.3 kg<u><br />
</u></li>
</ul>
<h6>Harms, hypoglycemic risk<sup>  </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>Repaglinide contraindicated when co-administered with clopidogrel or with gemfibrozil</li>
<li>Minimal to moderate risk of hypoglycemia</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>Dose given within 30 minutes of meal (not taken if meal skipped)</li>
<li>A minimum of 1 week should elapse between titration steps to assess response after each dose adjustment</li>
<li>Dosage adjustment usually determined by fasting BG</li>
<li>The preprandial dose can be doubled or increased up to 4mg (e.g., 0.5mg increase to 1mg, 1mg increase to 2mg or 2mg increase to 4mg)</li>
<li>Monitor: SCr and LFTs (baseline and periodically)</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Insulin secretagogues – sulfonylureas</span>
                    <h6>Gliclazide / Diamicron MR®<br> <img loading="lazy" decoding="async" src="https://tools.cep.health/wp-content/uploads/2021/11/pharmoption7.png" alt="" class="wp-image-44788" width="95" height="20"/></h6>
                    <p>SR tab: 30mg; ER tab: 60mg; generic available</p>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>A1C reduction (%):</strong></p>
<ul>
<li> 0.6-1.2</li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>Initial: 30mg MR po daily</li>
<li>Usual: 60mg MR daily</li>
<li>Max: 120mg MR daily</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>eGFR &lt;30mL/min (contraindicated)</li>
</ul>
<p><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></p>
<ul>
<li>Generic: $16</li>
<li>Trade: $37</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="VwsLTj">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="VwsLTj">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Gliclazide / Diamicron MR®</h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Neutral effect on CVD outcomes</li>
<li>Increase in all-cause mortality</li>
<li>Relatively rapid BG lowering response</li>
<li>Gliclazide preferred over glyburide due to potential lower hypoglycemic risk<u><br />
</u></li>
</ul>
<h6>Weight</h6>
<ul>
<li>Gain of 1.2-3.2 kg<u><br />
</u></li>
</ul>
<h6>Harms, hypoglycemic risk<sup>  </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>Minimal to moderate risk of hypoglycemia</li>
<li>Caution in older adults</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>Titrate up by 30mg every 2 weeks</li>
<li>Gliclazide MR 30mg = gliclazide 80mg</li>
<li>Gliclazide MR can be given once daily with breakfast</li>
<li>If CrCl &lt; 30mL/min, gliclazide is preferred</li>
<li>Monitor: SCr and LFTs (baseline and periodically)</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Insulin secretagogues – sulfonylureas </span>
                    <h6>Gliclazide / Diamicron®<br><img loading="lazy" decoding="async" src="https://tools.cep.health/wp-content/uploads/2023/08/icon_pg6_yellowclock.png" alt="" class="wp-image-44788" width="95" height="20"/></h6>
                    <p>80mg tab and generic available</p>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>A1C reduction (%):</strong></p>
<ul>
<li>0.6-1.2</li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>Initial: 40-80mg po daily in am cc</li>
<li>Usual: 80mg bid cc</li>
<li>Max: 160mg bid cc</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>eGFR &lt;30mL/min (contraindicated)</li>
</ul>
<p><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></p>
<ul>
<li>Generic: $29</li>
<li>Trade: $94</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="UYheb1">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="UYheb1">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Gliclazide / Diamicron®</h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Neutral effect on CVD outcomes</li>
<li>Increase in all-cause mortality</li>
<li>Relatively rapid BG lowering response</li>
<li>Gliclazide preferred over glyburide due to potential lower hypoglycemic risk<u><br />
</u></li>
</ul>
<h6>Weight</h6>
<ul>
<li>Gain of 1.2-3.2 kg<u><br />
</u></li>
</ul>
<h6>Harms, hypoglycemic risk<sup>  </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>Minimal to moderate risk of hypoglycemia</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>Titrate up by 80mg per week to target BG</li>
<li>For doses of 160mg, administer bid with meals</li>
<li>Monitor: SCr and LFTs (baseline and periodically)</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Insulin secretagogues – sulfonylureas </span>
                    <h6>Glimepiride / Amaryl®<br><img loading="lazy" decoding="async" src="https://tools.cep.health/wp-content/uploads/2021/11/pharmoption7.png" alt="" class="wp-image-44788" width="95" height="20"/></h6>
                    <p>1mg tab, 2mg tab, 4mg tab and generic available</p>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB X</li>
<li>NIHB X</li>
</ul>
<p><strong>A1C reduction (%):</strong></p>
<ul>
<li>0.6-1.2</li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>Initial: 1-2mg po daily in am cc</li>
<li>Usual: 1-4mg po daily in am cc</li>
<li>Max: 8mg po daily cc</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>eGFR &lt;30mL/min (contraindicated)</li>
</ul>
<p><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></p>
<ul>
<li>Generic: $62</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="EzO8Az">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="EzO8Az">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Glimepiride / Amaryl®</h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Neutral effect on CVD outcomes</li>
<li>Increase in all-cause mortality</li>
<li>Relatively rapid BG lowering response</li>
<li>Gliclazide preferred over glyburide due to potential lower hypoglycemic risk<u><br />
</u></li>
</ul>
<h6>Weight</h6>
<ul>
<li>Gain of 1.2-3.2 kg<u><br />
</u></li>
</ul>
<h6>Harms, hypoglycemic risk<sup>  </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>Moderate risk of hypoglycemia</li>
<li>Caution in older adults with poor renal function</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>After reaching a dose of 2mg, dosage increases should be made in increments of no more than 1mg at 1-2 week intervals based on BG response</li>
<li>Monitor: SCr and LFTs (baseline and periodically)</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Insulin secretagogues – sulfonylureas </span>
                    <h6>Glyburide / Diabeta®<sup>Ø</sup><br><img loading="lazy" decoding="async" src="https://tools.cep.health/wp-content/uploads/2023/08/icon_pg6_yellowclock.png" alt="" class="wp-image-44788" width="95" height="20"/></h6>
                    <p>2.5mg tab, 5mg tab and generic available</p>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB X</li>
</ul>
<p><strong>A1C reduction (%):</strong></p>
<ul>
<li>0.6-1.2</li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>Initial: 1.25-2.5 mg po daily cc</li>
<li>Usual: 5mg daily bid cc</li>
<li>Max: 10mg bid cc</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>eGFR &lt;60 (contraindicated)</li>
</ul>
<p><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></p>
<ul>
<li>Generic: $15</li>
<li>Trade: $37</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="NJ5lZP">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="NJ5lZP">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Glyburide / Diabeta®<sup>Ø</sup></h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Neutral effect on CVD outcomes</li>
<li>Increase in all-cause mortality</li>
<li>Relatively rapid BG lowering response</li>
<li>Gliclazide preferred over glyburide due to potential lower hypoglycemic risk<u><br />
</u></li>
</ul>
<h6>Weight</h6>
<ul>
<li>Gain of 1.2-3.2 kg<u><br />
</u></li>
</ul>
<h6>Harms, hypoglycemic risk<sup>  </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>Moderate risk of hypoglycemia</li>
<li>Caution in older adults with poor renal function</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>Continue initial dose for 5-7 days, then titrate by 2.5mg every 1-2 weeks</li>
<li>If patient consumes a light breakfast, defer 1st dose until lunchtime</li>
<li>If more than 10mg daily is required, the excess should be taken with the largest meal (e.g., evening meal)</li>
<li>To prevent hypoglycemia, do not skip meals after taking glyburide</li>
<li>Monitor: SCr and LFTs (baseline and periodically)</li>
<li>Caution in older adults with poor renal function</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading">SGLT2i or gliflozins</h6>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead">SGLT2i or gliflozins</span>
                    <h6>Canagliflozin / Invokana®<br><span style="font-size:9.0pt">Agent with evidence-based outcome benefits</span><br> <img loading="lazy" decoding="async" src="https://tools.cep.health/wp-content/uploads/2021/11/pharmoption8.png" alt="" class="wp-image-44788" width="122" height="20"/></h6>
                    <p>100mg tab and 300mg tab</p>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓ LU</li>
</ul>
<p><strong>A1C reduction (%):</strong></p>
<ul>
<li>0.5-0.7</li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>Initial/Usual: 100mg po od daily am</li>
<li>Max: 300mg daily</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>eGFR &lt;60mL/min (max dose 100mg daily)</li>
<li>eGFR &lt;60mL/min + UGT inducer (avoid)</li>
<li>eGFR &lt;45mL/min (caution)</li>
<li>eGFR &lt;30mL/min (contraindicated)</li>
</ul>
<p><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></p>
<ul>
<li>Trade: $321</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="Gjem3c">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="Gjem3c">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Canagliflozin / Invokana®</h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Reduced nephropathy progression and HHF in patients with ASCVD, CKD or high cardiovascular risk</li>
<li>Reduced MACE in patients with ASCVD or CKD</li>
<li>Reduced HHF in patients with HF</li>
</ul>
<h6>Weight</h6>
<ul>
<li>Loss of 2-3 kg<em><br />
</em></li>
</ul>
<h6>Harms, hypoglycemic risk<sup>  </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>Genital mycotic infections, urinary tract infections, hypotension, increased LDL-C, euglycemic diabetic ketoacidosis ± hyperglycemia (rare), fourniere’s gangrene (rare), acute kidney injury, orthostatic hypotension, increased urinary frequency <img loading="lazy" decoding="async" class="" src="https://tools.cep.health/wp-content/uploads/2021/11/kidney-protection-red.png" alt="" width="20" height="20" /></li>
<li>Caution with renal dysfunction, loop diuretics and older adults</li>
<li>Withhold treatment prior to major surgery or with serious illness/infections</li>
<li>Fracture risk, lower extremity amputation – avoid if prior amputation</li>
<li>Caution in acute dehydrating illness: On <a href="https://link.cep.health/t2dmnihtml4" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">SADMANS</a> list</li>
<li>Increase risk of hypoglycemia when in combination with sulfonylurea or insulin</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>Monitor: blood pressure, weight, SCr, potassium, blood ketones if diabetic ketoacidosis symptoms (baseline, within 2-4 weeks of starting, then periodically)</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">SGLT2i or gliflozins</span>
                    <h6>Dapagliflozin / Forxiga®<br><span style="font-size:9.0pt">Agent with evidence-based outcome benefits</span><br> <img loading="lazy" decoding="async" src="https://tools.cep.health/wp-content/uploads/2021/11/pharmoption8.png" alt="" class="wp-image-44788" width="122" height="20"/></h6>
                    <p>5mg tab and 10mg tab</p>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>A1C reduction (%):</strong></p>
<ul>
<li>0.5-0.7</li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>Initial/Usual: 5mg po daily am</li>
<li>Max: 10mg po daily am</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>eGFR &lt; 25mL/min (contraindicated)</li>
</ul>
<p><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></p>
<ul>
<li>Trade: $84</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="EQsz9M">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="EQsz9M">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Dapagliflozin / Forxiga®</h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Reduced nephropathy progression and HHF in patients with ASCVD, CKD or high cardiovascular risk</li>
<li>Reduced all-cause death in patient with HF or CKD</li>
<li>Reduced HHF and CV death, benefits if patients is comorbid with HFrEF or HFpEF</li>
</ul>
<h6>Weight</h6>
<ul>
<li>Loss of 2-3 kg<em><br />
</em></li>
</ul>
<h6>Harms, hypoglycemic risk<sup> </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>Genital mycotic infections, urinary tract infections, hypotension, increased LDL-C, euglycemic diabetic ketoacidosis ± hyperglycemia (rare), fourniere’s gangrene (rare), acute kidney injury, orthostatic hypotension, increased urinary frequency <img loading="lazy" decoding="async" class="" src="https://tools.cep.health/wp-content/uploads/2021/11/kidney-protection-red.png" alt="" width="20" height="20" /></li>
<li>Caution with renal dysfunction, loop diuretics and older adults</li>
<li>Withhold treatment prior to major surgery or with serious illness/infections</li>
<li>Avoid in bladder cancer</li>
<li>Caution in acute dehydrating illness: On <a href="https://link.cep.health/t2dmnihtml4" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">SADMANS</a> list</li>
<li>Increase risk of hypoglycemia when in combination with sulfonylurea or insulin</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>Monitor: blood pressure, weight, SCr, potassium, blood ketones if diabetic ketoacidosis symptoms (baseline, within 2-4 weeks of starting, then periodically)</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">SGLT2i or gliflozins</span>
                    <h6>Empagliflozin / Jardiance®<br><span style="font-size:9.0pt">Agent with evidence-based outcome benefits</span><br> <img loading="lazy" decoding="async" src="https://tools.cep.health/wp-content/uploads/2021/11/pharmoption8.png" alt="" class="wp-image-44788" width="122" height="20"/></h6>
                    <p>10mg tab and 25mg tab</p>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>A1C reduction (%):</strong></p>
<ul>
<li>0.5-0.7</li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>Initial/Usual: 10mg po daily am</li>
<li>Max: 10-25mg po daily am</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>eGFR &lt;60mL/min (caution)</li>
<li>eGFR &lt;20mL/min (contraindicated)</li>
</ul>
<p><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></p>
<ul>
<li>Trade: $304</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="3ztjy4">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="3ztjy4">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Empagliflozin / Jardiance®</h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Reduced nephropathy, HHF in patients with ASCVD, CKD or HF (HFrEF)</li>
<li>Reduced MACE in patients with ASCVD or CKD</li>
<li>Reduction of HHF and CV death if patient is comorbid with HFpEF</li>
</ul>
<h6>Weight</h6>
<ul>
<li>Loss of 2-3 kg<em><br />
</em></li>
</ul>
<h6>Harms, hypoglycemic risk<sup>  </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>Genital mycotic infections, urinary tract infections, hypotension, increased LDL-C, euglycemic diabetic ketoacidosis ± hyperglycemia (rare), fourniere’s gangrene (rare), acute kidney injury, orthostatic hypotension, increased urinary frequency <img loading="lazy" decoding="async" class="" src="https://tools.cep.health/wp-content/uploads/2021/11/kidney-protection-red.png" alt="" width="20" height="20" /></li>
<li>Caution with renal dysfunction, loop diuretics and older adults</li>
<li>Withhold treatment prior to major surgery or with serious illness/infections</li>
<li>Caution in acute dehydrating illness: On <a href="https://link.cep.health/t2dmnihtml4" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">SADMANS</a> list</li>
<li>Increase risk of hypoglycemia when in combination with sulfonylurea or insulin</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>Monitor: blood pressure, weight, SCr, potassium, blood ketones if diabetic ketoacidosis symptoms (baseline, within 2-4 weeks of starting, then periodically)</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading">TZD</h6>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead">TZD</span>
                    <h6>Pioglitazone HCL / Actos®<sup>Ø</sup> <br> <img loading="lazy" decoding="async" src="https://tools.cep.health/wp-content/uploads/2021/11/pharmoption9.png" alt="" class="wp-image-44788" width="70" height="20"/></h6>
                    <p>15mg tab, 30mg tab, 45mg tab and generic available</p>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB X <a href="https://link.cep.health/t2dmnihtml6" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">EAP</a></li>
<li> NIHB ✓</li>
</ul>
<p><strong>A1C reduction (%):</strong></p>
<ul>
<li>0.7-0.9</li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>Initial: 15mg daily po daily</li>
<li>Usual: 30-45mg po daily</li>
<li>Max: 45mg po daily</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>eGFR &lt;60mL/min (caution)</li>
</ul>
<p><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></p>
<ul>
<li>Generic: $247–$366</li>
<li>Trade:$388-$578</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="GHplnX">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="GHplnX">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Pioglitazone HCL / Actos®<sup>Ø</sup></h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Reduced MACE, reduced MI, reduced stroke <img loading="lazy" decoding="async" class="" src="https://tools.cep.health/wp-content/uploads/2021/11/cvd-green.png" alt="" width="20" height="20" /></li>
</ul>
<h6>Weight</h6>
<ul>
<li>Gain of 2-5 kg<u><br />
</u></li>
</ul>
<h6>Harms, hypoglycemic risk<sup>  </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>Edema, HF, fractures, increased HDL-C, macular edema (rare), contraindicated in HF</li>
<li>Possible bladder risk</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>4–12 weeks for max effect</li>
<li>Increase by 15mg every 4 weeks</li>
<li>Monitor: SCr and LFTs (baseline and periodically)</li>
<li>Risk of heart failure, which may be higher if combined with insulin (combination not approved in Canada)</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">TZD</span>
                    <h6>Rosiglitazone / Avandia®<sup>Ø</sup> <br> <img loading="lazy" decoding="async" src="https://tools.cep.health/wp-content/uploads/2021/11/pharmoption9.png" alt="" class="wp-image-44788" width="70" height="20"/></h6>
                    <p>2mg tab, 4mg tab, 8mg tab and generic available</p>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB X <a href="https://link.cep.health/t2dmnihtml6" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">EAP</a></li>
<li>NIHB X</li>
</ul>
<p><strong>A1C reduction (%)</strong></p>
<ul>
<li>0.7-0.9</li>
</ul>
<p><strong>Dose:</strong></p>
<ul>
<li>Initial: 4mg po daily</li>
<li>Usual: 4mg po daily to bid</li>
<li>Max: 8mg po daily</li>
</ul>
<p><strong>Renal dose:</strong></p>
<ul>
<li>eGFR &lt;60mL/min (caution)</li>
</ul>
<p><strong>Drug cost </strong><strong>for usual </strong><strong>dose* </strong><strong>($/100 </strong><strong>days):</strong></p>
<ul>
<li>Generic: $207</li>
<li>Trade: $292</li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="N9Q4xo">View benefits and CVD outcome, weight, harms and hypoglycemic risk, and comments</a>
                                      </div>
                                      <div class="modal" data-modal="N9Q4xo">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                          <h4>Rosiglitazone / Avandia®<sup>Ø</sup></h4>
                                                                                      <h6>Other benefits, CVD outcomes</h6>
<ul>
<li>Possible MI risk <img loading="lazy" decoding="async" class="" src="https://tools.cep.health/wp-content/uploads/2021/11/cvd-red.png" alt="" width="20" height="20" /></li>
</ul>
<h6>Weight</h6>
<ul>
<li>Gain of 2-5 kg<u><br />
</u></li>
</ul>
<h6>Harms, hypoglycemic risk<sup>  </sup>(negligible risk as monotherapy unless stated otherwise)</h6>
<ul>
<li>Edema, HF, fractures, increased HDL-C, macular edema (rare), contraindicated in HF</li>
</ul>
<h6><strong>Comments (titration, administration, monitoring, notes)</strong></h6>
<ul>
<li>4–12 weeks for max effect</li>
<li>Increase to 8mg daily in 8-12 weeks if BG not at target</li>
<li>Monitor: SCr and LFTs (baseline and periodically)</li>
<li>Risk of heart failure, which may be higher if combined with insulin (combination not approved in Canada)</li>
<li>Requires special authorization from patient prior to prescribing</li>
<li><a href="https://link.cep.health/t2dmnihtml7" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Health Canada restrictions</a>: rosiglitazone only to be used when all other oral agents have been tried alone or together and targets not reached</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">Combination products<sup>29,30,39,40-42</sup></h3>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>Refer to individual components in <a href="#non-insulin">Non-insulin pharmacotherapy table</a> for maximum dose, renal dose, comments</p>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Insulin degludec/liraglutide (Xultophy®)</h6>
                    <p>100 units/mL insulin degludec, 3.6mg/mL</p>
<p><strong>Usual dose:</strong></p>
<ul>
<li>16 units/0.58mg – 50 units/1.8mg subcut daily (50 units insulin daily)</li>
</ul>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB X</li>
<li>NIHB X</li>
</ul>
<p><strong>Drug cost for usual dose* ($/100 days):</strong></p>
<ul>
<li>Trade: $1065</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Insulin glargine/lixisenatide (Soliqua®) </h6>
                    <p>100U/mL, 33mcg/mL</p>
<p><strong>Usual dose:</strong></p>
<ul>
<li>15 units/5mcg – 60 units/20mcg; subcut daily (60 units insulin daily)</li>
</ul>
<p><strong>Coverage:</strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Drug cost for usual dose* ($/100 days):</strong></p>
<ul>
<li>Trade: $624</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Metformin/canagliflozin (Invokamet®)</h6>
                    <p><strong>Not on Ontario drug formulary</strong></p>
<p>500/50mg, 850/50mg, 1000/50mg, 500/150mg, 850,150mg and 1000/150mg</p>
<p><strong>Usual dose:</strong></p>
<ul>
<li>1 tab po bid cc</li>
</ul>
<p><strong>Coverage:</strong></p>
<ul>
<li>ODB X</li>
<li>NIHB X</li>
</ul>
<p><strong>Drug cost for usual dose* ($/100 days):</strong></p>
<ul>
<li>Trade: $386</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Metformin/dapagliflozin (Xigduo®)</h6>
                    <p>850/5mg, 1000/5mg and generic available</p>
<p><strong>Usual dose:</strong></p>
<ul>
<li>1 tab po bid cc</li>
</ul>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Drug cost for usual dose* ($/100 days):</strong></p>
<ul>
<li>G: $148</li>
<li>Trade: $273</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Metformin/empagliflozin (Synjardy®)</h6>
                    <p>500/5mg, 850/5mg, 1000/5mg, 500/12.5mg, 850/12.5mg and 1000/12.5mg</p>
<p><strong>Usual dose:</strong></p>
<ul>
<li>1 tab po bid cc</li>
</ul>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Drug cost for usual dose* ($/100 days):</strong></p>
<ul>
<li>Trade: $307</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Metformin/linagliptin (Jentadueto®)</h6>
                    <p>500/2.5mg, 850/2.5mg and 1000/2.5mg</p>
<p><strong>Usual dose:</strong></p>
<ul>
<li>1 tab po bid cc</li>
</ul>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Drug cost for usual dose* ($/100 days):</strong></p>
<ul>
<li>Trade: $311</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Metformin/saxagliptin (Komboglyze®)</h6>
                    <p>500/2.5mg, 850/2.5mg and 1000/2.5mg</p>
<p><strong>Usual dose:</strong></p>
<ul>
<li>1 tab po bid cc</li>
</ul>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Drug cost for usual dose* ($/100 days):</strong></p>
<ul>
<li>Trade: $283</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Metformin/sitagliptin (Janumet®)</h6>
                    <p>500/50mg, 850/50mg and 1000/50mg</p>
<p><strong>Usual dose:</strong></p>
<ul>
<li>1 tab po bid cc</li>
</ul>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓</li>
</ul>
<p><strong>Drug cost for usual dose* ($/100 days):</strong></p>
<ul>
<li>Trade: $107</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Metformin/sitagliptin (Janumet XR®)</h6>
                    <p>ER tab: 500/50mg, 1000/50mg and 1000/100mg</p>
<p><strong>Usual dose:</strong></p>
<ul>
<li>1-2 tab(s) po once daily cc</li>
</ul>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB ✓</li>
<li>NIHB ✓ LU <span style="font-size: 9.0pt;">(for patients who did not achieve glycemic control or who demonstrated intolerance to an adequate trial of metformin and a sulfonylurea)</span></li>
</ul>
<p><strong>Drug cost for usual dose* ($/100 days):</strong></p>
<ul>
<li>Trade: $107</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Metformin/alogliptin (Kazano)</h6>
                    <p>1000/12.5mg, 850/12.5mg, 500/12.5mg</p>
<p><strong>Usual dose:</strong></p>
<ul>
<li>1 tab po bid cc</li>
</ul>
<p><strong>Coverage: </strong></p>
<ul>
<li>ODB X</li>
<li>NIHB X</li>
</ul>
<p><strong>Drug cost for usual dose* ($/100 days):</strong></p>
<ul>
<li>Trade: $286</li>
</ul>
                                      </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p class="has-small-font-size" id="definitions"><strong>DPP4i</strong>: Dipeptidyl peptidase-4 inhibitors; <strong>GLP1-RA</strong>: Glucagon-like peptide-1 receptor agonists; <strong>SGLT2i</strong>: Sodium-glucose cotransporter-2 inhibitors; <strong>TZD</strong>: Thiazolidinediones<br><em><strong><u>underlined text</u></strong></em>: important information,<strong> *</strong>= prices reflect cost to consumer and include markup and dispensing fee, <strong>– </strong>= weight neutral, <strong>ac</strong> = before meals, <strong>AE</strong> = adverse events, <strong>BG</strong> = blood glucose, <strong>bid</strong> = twice daily, <strong>cc</strong> = with meal, <strong>CrCl</strong> = creatinine clearance, <strong>CV</strong> = cardiovascular, <strong>CVD</strong> = cardiovascular disease, <strong>EAP</strong> = Exceptional Access Program, <strong>eGFR</strong> = estimated glomerular filtration rate, <strong>ER</strong> = extended release, <strong>GI</strong> = gastrointestinal, <strong>HCL</strong> = hydrochloric acid, <strong>HDL-C</strong> = high density lipoprotein cholesterol, <strong>HF</strong> = heart failure, <strong>LDL-C</strong> = low density lipoprotein cholesterol, <strong>LFTs</strong> = liver function tests, <strong>LU</strong> = limited use, <strong>MACE</strong> = major adverse cardiovascular event, <strong>max</strong> = maximum, <strong>MI</strong> = myocardial infarction, <strong>μg</strong> = microgram, <strong>mg</strong> = milligram, <strong>mL</strong> = milliliter, <strong>MR</strong> = modified release, <strong>NIHB</strong> = non-insured health benefits for First Nations and Inuit, <strong>ODB</strong> = Ontario Drug Benefit, <strong>po</strong> = by mouth, <strong>qid</strong> = four times daily, <strong>Subcut</strong> = subcutaneous, <strong>SCr</strong> = serum creatinine, <strong>SR</strong> = sustained release, <strong>Tab</strong> = tablets, <strong>tid</strong> = three times daily, <strong>UGT</strong> = UDP-glucuronosyltransferase, <strong>Ø</strong> = discontinued brand name</p>
</div></article>						</div>
					</div>
				</section>
							<section class="main-section" id="resources" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Resources								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--support-materials ">

  <div class="container default">
    <div class="inner">
              <div class="columns">
                      <div class="column icon">
              <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/support-materials.svg" />
            </div>
                                <div class="column">
              <strong class="heading"><h6>Patient resource</h6></strong>
            </div>
                  </div>
                    <ul>
<li><a href="https://link.cep.health/t2dmnihtml8" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Diabetes Canada Hypoglycemia low blood sugar in adults</a></li>
<li><a href="https://link.cep.health/t2dmnihtml9" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Diabetes Canada Drive safe with diabetes</a></li>
<li><a href="https://link.cep.health/t2dmnihtml10" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Diabetes Canada Stay safe when you have diabetes and are sick or at risk of dehydration</a></li>
<li><a href="https://link.cep.health/t2dmnihtml4" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">RxFiles Type 2 diabetes and sick days: Medications to pause</a></li>
<li><a href="https://link.cep.health/t2dmnihtml11" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Centre for Effective Practice local services for patients living with type 2 diabetes</a></li>
</ul>
          </div>
  </div>

</article>						</div>
					</div>
				</section>
							<section class="main-section" id="references" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								References								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--references ">
<div class="container">

                        <ul>
               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [1]
                    </div>

                    <div class="column">
                      <p>Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2018;42(Suppl 1):S1–325.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [2]
                    </div>

                    <div class="column">
                      <p>Punthakee Z, Goldenberg R, Katz P. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. 2018;42(Suppl 1): S10–S15. Table 4, Advantages and disadvantages of diagnostic tests for diabetes; p. S12.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [3]
                    </div>

                    <div class="column">
                      <p>Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA, et al. Hemoglobin A1C targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: A guidance statement update from the American College of Physicians. Ann Intern Med. 2018 Apr 17;168(8):569.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [4]
                    </div>

                    <div class="column">
                      <p>Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Zuñiga-Hernandez JA, McCoy RG. Benefits and harms of intensive glycemic control in patients with type 2 diabetes. BMJ. 2019 Nov 5;l5887.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [5]
                    </div>

                    <div class="column">
                      <p>The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545–59.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [6]
                    </div>

                    <div class="column">
                      <p>UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet. 1998 Sep;352(9131):854–65.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [7]
                    </div>

                    <div class="column">
                      <p>Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016 Jul 28;375(4):311–22.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [8]
                    </div>

                    <div class="column">
                      <p>Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117–28.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [9]
                    </div>

                    <div class="column">
                      <p>Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295–306.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [10]
                    </div>

                    <div class="column">
                      <p>Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016 Nov;375:1834-1844.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [11]
                    </div>

                    <div class="column">
                      <p>Juma S, Taabazuing M-M, Montero-Odasso M. Clinical frailty scale in an acute medicine unit: a simple tool that predicts length of stay. Can Geriatr J. 2016 Jun 29;19(2):34–9.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [12]
                    </div>

                    <div class="column">
                      <p><span style="font-weight: 400;">Diabetes Canada Clinical Practice Guidelines Expert Committee. Chapter 37: Diabetes in older people [Internet]. 2018 [cited (2023 Jun 23)]. Available from: <a href="https://link.cep.health/t2dminhmtl80" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.diabetes.ca/health-care-providers/clinical-practice-guidelines/chapter-37#panel-tab_FullText</a></span></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [13]
                    </div>

                    <div class="column">
                      <p>Diabetes Canada Clinical Practice Guidelines Expert Committee. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. Canadian Journal of Diabetes. 2020 Oct 1;44(7):575-591.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [14]
                    </div>

                    <div class="column">
                      <p>RxFiles. Update on type 2 diabetes non-insulin pharmacotherapy [Internet]. Winter 2019/2020 [cited 2020 Sept 16]. Available from: <a href="https://link.cep.health/t2dmnihtml12" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.rxfiles.ca</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [15]
                    </div>

                    <div class="column">
                      <p><span style="font-weight: 400;">The EMPA-KIDNEY Collaborative Group, Herrington W.G., Staplin N, Wanner C, Green J.B, Hause S.J., Emberson J.R., et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023 Jan 12;388(2):117-127.</span></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [16]
                    </div>

                    <div class="column">
                      <p><span style="font-weight: 400;">Solomon S.D., McMurray J.J.V., Claggett B, de Boer R.A., DeMets D, Hernandez A.F., Inzucchi S.E., et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022; 387:1089-1098.</span></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [17]
                    </div>

                    <div class="column">
                      <p><span style="font-weight: 400;">Packer M, Anker S.D., Butler J, Filippatos G, Pocock S.J., Carson P, Januzzi J, Verma S, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383:1413-1424.</span></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [18]
                    </div>

                    <div class="column">
                      <p><span style="font-weight: 400;">McMurray J.J.V., Solomon S.D., Inzucchi S.E., Køber L, Kosiborod M.N., Martinez F.A., Ponikowski P, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381:1995-2008.</span></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [19]
                    </div>

                    <div class="column">
                      <p><span style="font-weight: 400;">Heerspink H.J.L., Stefánsson B.V., Correa-Rotter R, Chertow G.M., Greene T, Hou F.F., et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:1436-1446.</span></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [20]
                    </div>

                    <div class="column">
                      <p><span style="font-weight: 400;">Lipscombe L, Butalia S, Dasgupta K, Eurich DT, MacCallum L, Shah BR, et al. Pharmacologic </span><span style="font-weight: 400;">glycemic management of type 2 diabetes in adults: 2020 update. Canadian Journal of Diabetes. 2020 Oct 1;44(7):575–91.</span></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [21]
                    </div>

                    <div class="column">
                      <p><span style="font-weight: 400;">American Diabetes Association. Introduction: Standards of medical care in diabetes &#8211; 2021. DiaCare. 2021 Jan;44(Supplement 1):S1–2.</span></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [22]
                    </div>

                    <div class="column">
                      <p><span style="font-weight: 400;">Senior PA, Houlden RL, Kim J, Mackay D, Nagpal S, Rabi D, et al. Pharmacologic glycemic </span><span style="font-weight: 400;">management of type 2 diabetes in adults: 2020 update &#8211; The users guide. Canadian Journal of Diabetes. 2020 Oct 1;44(7):592–6.</span></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [23]
                    </div>

                    <div class="column">
                      <p><span style="font-weight: 400;">Mayo Clinic. Hyperglycemia in diabetes &#8211; Symptoms and causes [Internet]. 2020 [cited 2021 Jan 14]. Available from: <a href="https://link.cep.health/t2dmnoninhmtl9" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.mayoclinic.org/diseases-conditions/hyperglycemia/symptomscauses/syc-20373631</a></span></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [24]
                    </div>

                    <div class="column">
                      <p>Saheb Kashaf M, McGill ET, Berger ZD. Shared decision-making and outcomes in type 2 diabetes: A systematic review and meta-analysis. Patient Educ Couns. 2017 Dec;100(12):2159–71.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [25]
                    </div>

                    <div class="column">
                      <p>RxFiles. Shared decision making in diabetes [Internet]. 2020 [cited 2020 Aug 18]. Available from: <a href="https://link.cep.health/t2dmnihtml12" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.rxfiles.ca</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [26]
                    </div>

                    <div class="column">
                      <p>Mayo Clinic. Diabetes medication choice [Internet]. 2016 [cited 2020 Aug 18]. Available from: <a href="https://link.cep.health/t2dmnihtml13" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://shareddecisions.mayoclinic.org/decision-aid-information/decision-aids-for-chronicdisease/diabetes-medication-management/</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [27]
                    </div>

                    <div class="column">
                      <p><span style="font-weight: 400;">Frias J.P., Davies M.J., Rosenstock J, Manghi F.C.P., Lando F.P., Bergman B.K., et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021; 385:503-515</span></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [28]
                    </div>

                    <div class="column">
                      <p><span style="font-weight: 400;">Eli Lilly Canada Inc. Product monograph including patient information: Mounjaro™ [Internet]. 2022 [cited (2023 Jun 23)]. Available from: </span><a href="https://link.cep.health/t2dmnoninhmtl8" data-wpel-link="external" target="_blank" rel="external noopener noreferrer"><span style="font-weight: 400;">https://pdf.hres.ca/dpd_pm/00068421.PDF</span></a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [29]
                    </div>

                    <div class="column">
                      <p>Government of Ontario, Ministry of Health. Ontario Drug Benefit Formulary [Internet]. [cited 2020 Aug 4]. Available from: <a href="https://link.cep.health/t2dmnihtml14" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.formulary.health.gov.on.ca/formulary</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [30]
                    </div>

                    <div class="column">
                      <p>RxFiles. Anti-hyperglycemic type 2 diabetes agents: Drug comparison chart [Internet]. 2020 [cited 2020 Aug 6]. Available from: <a href="https://link.cep.health/t2dmnihtml12" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.rxfiles.ca/</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [31]
                    </div>

                    <div class="column">
                      <p>Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, et al. A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care. 2002 Oct;25(10):1737-1743.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [32]
                    </div>

                    <div class="column">
                      <p>RxFiles. Type 2 diabetes and sick days medications to pause [Internet]. Available from: <a href="https://link.cep.health/t2dmnihtml4" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.rxfiles.ca/rxfiles/uploads/documents/SADMANS-Rx.pdf</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [33]
                    </div>

                    <div class="column">
                      <p>Takeda Canada Inc. Product monograph: Nesina® [Internet]. 2019 [cited 2020 Aug 10]. Available from: <a href="https://link.cep.health/t2dmnihtml16" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.takeda.com/siteassets/en-ca/home/what-we-do/our-medicines/product-monographs/nesina/nesina-pm-en.pdf/</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [34]
                    </div>

                    <div class="column">
                      <p>Eli Lilly Canada Inc. Product monograph: Trulicity® [Internet]. 2019 [cited 2020 Aug 10]. Available from: <a href="https://link.cep.health/t2dmnihtml18" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">http://pi.lilly.com/ca/trulicity-ca-pm.pdf</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [35]
                    </div>

                    <div class="column">
                      <p>Novo Nordisk Canada Inc. Product monograph: Victoza® [Internet]. 2020 [cited 2020 Aug 10]. Available from: <a href="https://link.cep.health/t2dmnihtml20" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/victoza-product-monograph.pdf</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [36]
                    </div>

                    <div class="column">
                      <p>Novo Nordisk Canada Inc. Product monograph: Rybelsus® [Internet]. 2020 [cited 2020 Aug 10]. Available from: <a href="https://link.cep.health/t2dmnoninhmtl10" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/Rybelsus-PM-EN-monograph.pdf</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [37]
                    </div>

                    <div class="column">
                      <p><span style="font-weight: 400;">GlaxoSmithKline Inc. Health Canada Endorsed Information on Important New Restrictions on the use of rosiglitazone (Pr AVANDIA ®, Pr AVANDAMET ® and Pr AVANDARYL ®) [Internet]. 2010. [cited (2023 June 23)]. Available from: </span><a href="https://link.cep.health/t2dmnoninhmtl11" data-wpel-link="external" target="_blank" rel="external noopener noreferrer"><span style="font-weight: 400;">https://ca.gsk.com/media/6145/hcpletter.pdf</span></a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [38]
                    </div>

                    <div class="column">
                      <p><span style="font-weight: 400;"><a href="https://link.cep.health/expertopinionrationale" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Expert opinion</a>.</span></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [39]
                    </div>

                    <div class="column">
                      <p>Indigenous Services Canada. Non-insured health benefits, First Nations and Inuit Health Branch: Drug benefit list [Internet]. 2020. Available from: <a href="https://link.cep.health/t2dmnihtml15" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.sac-isc.gc.ca/DAM/DAM-ISC-SAC/DAM-HLTH/STAGING/texte-text/nihb_benefits-services_drugs_dbl-index_1573154657223_eng.pdf</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [40]
                    </div>

                    <div class="column">
                      <p>Janssen Inc. Product monograph: Invokamet® [Internet]. 2019 [cited 2020 Aug 12]. Available from: <a href="https://link.cep.health/t2dmnihtml24" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://pdf.hres.ca/dpd_pm/00051078.PDF</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [41]
                    </div>

                    <div class="column">
                      <p>AstraZeneca Canada Inc. Product monograph: Komboglyze® [Internet]. 2018 [cited 2020 Aug 12]. Available from: <a href="https://link.cep.health/t2dmnihtml25" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/komboglyze-product-monograph-en.pdf</a></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [42]
                    </div>

                    <div class="column">
                      <p><span style="font-weight: 400;">Takeda Canada Inc. Product monograph including patient medication information: Kazano® [Internet]. 2018 [cited (2023 Jun 23)].</span></p>
                    </div>
                  </li>

                            </ul>
           
</div>
</article>						</div>
					</div>
				</section>
							<section class="main-section" id="acknowledgments-and-legal" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Acknowledgments and legal								
    <span class="badge new" data-last-modified="Jun 23, 2023" data-hide-on-click>New</span>
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--legal-text ">
<div class="container">
  <div class="columns is-gapless">
    <div class="column is-8 text">
      <div class="inner">
        <p>The Type 2 diabetes: Non-insulin pharmacotherapy tool (‘Tool’) was developed as part of the Knowledge Translation in Primary Care Initiative, led by the Centre for Effective Practice, in collaboration with the Nurse Practitioners’ Association of Ontario. Clinical leadership for the development of the Tool was provided by Dr. Risa Bordman and was subject to external review by health care providers and other relevant stakeholders. This Tool was funded by the Government of Ontario as part of the Knowledge Translation in Primary Care Initiative.</p>
<p>This Tool was developed for licensed health care professionals in Ontario as a guide only and does not constitute medical or other professional advice. Health care professionals are required to exercise their own clinical judgement in using this Tool. Neither the Centre for Effective Practice (“CEP”), Government of Ontario, Nurse Practitioners’ Association of Ontario, nor any of their respective agents, appointees, directors, officers, employees, contractors, members or volunteers: (i) are providing medical, diagnostic or treatment services through this Tool; (ii) to the extent permitted by applicable law, accept any responsibility for the use or misuse of this Tool by any individual including, but not limited to, primary care providers or entity, including for any loss, damage or injury (including death) arising from or in connection with the use of this Tool, in whole or in part; or (iii) give or make any representation, warranty or endorsement of any external sources referenced in this Tool (whether specifically named or not) that are owned or operated by their parties, including any information or advice contained therein.</p>
<p><img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/CCLicense.svg" alt="" /></p>
<p><em>This Tool is a product of the Centre for Effective Practice. Permission to use, copy, and distribute this material is for all noncommercial and research purposes is granted, provided the above disclaimer, this paragraph and the following paragraphs, and appropriate citations appear in all copies, modifications, and distributions. Use of this Tool for commercial purposes or any modifications of the Tool are subject to charge and must be negotiated with the Centre for Effective Practice (Email: <a href="mailto:info@cep.health">info@cep.health</a>).</em></p>
<p>For statistical and bibliographic purposes, please notify the Centre for Effective Practice (<a href="mailto:info@cep.health">info@cep.health</a>) of any use or reprinting of the Tool. Please use the following citation when referencing the Tool: Reprinted with Permission from Centre for Effective Practice. (June 2023). Type 2 diabetes: Non-insulin pharmacotherapy: Ontario. Toronto: Centre for Effective Practice.</p>
<p>&nbsp;</p>
      </div>
    </div>
    <div class="column is-4 logos">
      <div class="inner">
                  <div>
            
                <p>
                  Developed by                </p>

                
                  <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/CEP-Logo-Color.svg" />

                
            
                <p>
                  In collaboration                </p>

                
                  <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/NPAO-Logo.svg" />

                
                      </div>
              </div>
    </div>
  </div>
</div>
</article>						</div>
					</div>
				</section>
			
		</section>
  </main>

<div class="utility-bar">
    <button data-search-tool-open class="utility-button search-button"><i class="icon icon-search"></i></button>
    <a href="#top-of-sections" class="utility-button back-to-top"><i class="icon icon-arrow-up"></i></a>
</div>
<div class="global-modal"></div>

<script type="speculationrules">
{"prefetch":[{"source":"document","where":{"and":[{"href_matches":"\/*"},{"not":{"href_matches":["\/wp-*.php","\/wp-admin\/*","\/wp-content\/uploads\/*","\/wp-content\/*","\/wp-content\/plugins\/*","\/wp-content\/themes\/cep-tools\/*","\/*\\?(.+)"]}},{"not":{"selector_matches":"a[rel~=\"nofollow\"]"}},{"not":{"selector_matches":".no-prefetch, .no-prefetch a"}}]},"eagerness":"conservative"}]}
</script>
<!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: Obesity management HTML - enhance confidence -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'hhgajtyemrlknjsvrsd5');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: RSV HTML - change in patient care -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'tkia37pcyyahx6opqim2');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML Secure Messaging -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'ngtztpck7tvpbcvakl7d');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 AI LC - fill knowledge gaps -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'f2bzjhvjmeyfqkxxjggz');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML Social Rxing -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'qgchslypk4toxdtgsfsf');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML COPD -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'cfontzigzdapzyxtbhg4');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML Type 2 DM Insulin -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'nflzw9az1mcray2ltc4m');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML Type 2 DM Non-Insulin -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'edlo1w0s0lujgciyjgf9');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML ME/CFS -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'ybbyul2ujyofvsznkiti');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML FM -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'doewskxay35gb860nodl');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML Role Q -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'wm0xaeyycxvhthxjz76n');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML POTS -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'iqff27bs0pszfabitkgw');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML HF -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'xfup8pda84l5bd0udyje');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML A&D -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'xokl1h6esysgo5wdkq9d');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2022.11 E2P Patient Resource Page -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'jaxkt0icjnuu0z43iuik');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.11 MAID - Measuring knowledge -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'vso3vlstnsfjgeuogzry');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.11 Fall Prevention & MGMT Resource - Fill knowledge gaps -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'awihu5noxqqj5s7iasv8');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.08 PPIs - Change prescribing -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'cdikvvptidch9oj1o56k');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.08 Chronic Insomnia HTML - Increase Confidence -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'qeu7gqedkzjnotzskhln');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.08 Non-Medical Cannabis Resource - Fill knowledge gaps -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'okkbvdzprjjylm7wjkhe');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.07 ADHD Resource - Fill knowledge gaps -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'rxekv8i4pwnmp4zvclcm');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2020.05 COVID-19 - Change the way you will provide care for your patients? -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'koz3ranojk5yi8c5wmpe');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2020.07 CNCP - change in patient care -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'e6m4njfonyv93sqcttlx');</script>
<!-- / OptinMonster -->		<!-- Google Tag Manager (noscript) snippet added by Site Kit -->
		<noscript>
			<iframe src="https://www.googletagmanager.com/ns.html?id=GTM-WLFDZV" height="0" width="0" style="display:none;visibility:hidden"></iframe>
		</noscript>
		<!-- End Google Tag Manager (noscript) snippet added by Site Kit -->
				<script type="text/javascript">
		var hhgajtyemrlknjsvrsd5_shortcode = true;var tkia37pcyyahx6opqim2_shortcode = true;var ngtztpck7tvpbcvakl7d_shortcode = true;var f2bzjhvjmeyfqkxxjggz_shortcode = true;var qgchslypk4toxdtgsfsf_shortcode = true;var cfontzigzdapzyxtbhg4_shortcode = true;var nflzw9az1mcray2ltc4m_shortcode = true;var edlo1w0s0lujgciyjgf9_shortcode = true;var ybbyul2ujyofvsznkiti_shortcode = true;var doewskxay35gb860nodl_shortcode = true;var wm0xaeyycxvhthxjz76n_shortcode = true;var iqff27bs0pszfabitkgw_shortcode = true;var xfup8pda84l5bd0udyje_shortcode = true;var xokl1h6esysgo5wdkq9d_shortcode = true;var jaxkt0icjnuu0z43iuik_shortcode = true;var vso3vlstnsfjgeuogzry_shortcode = true;var awihu5noxqqj5s7iasv8_shortcode = true;var cdikvvptidch9oj1o56k_shortcode = true;var qeu7gqedkzjnotzskhln_shortcode = true;var okkbvdzprjjylm7wjkhe_shortcode = true;var rxekv8i4pwnmp4zvclcm_shortcode = true;var koz3ranojk5yi8c5wmpe_shortcode = true;var e6m4njfonyv93sqcttlx_shortcode = true;		</script>
		<style id='core-block-supports-inline-css' type='text/css'>
.wp-container-core-columns-is-layout-9d6595d7{flex-wrap:nowrap;}
</style>
<script>(function(d){var s=d.createElement("script");s.type="text/javascript";s.src="https://a.omappapi.com/app/js/api.min.js";s.async=true;s.id="omapi-script";d.getElementsByTagName("head")[0].appendChild(s);})(document);</script><script type="text/javascript" src="https://tools.cep.health/wp-content/themes/cep-tools/js/vendor.min.js" id="vendor-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-content/themes/cep-tools/js/app.min.js?ver=1674670088" id="app-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-content/plugins/glossary-by-codeat/assets/js/off-screen.js?ver=2.3.5" id="glossary-off-screen-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-includes/js/dist/dom-ready.min.js?ver=f77871ff7694fffea381" id="wp-dom-ready-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-includes/js/dist/hooks.min.js?ver=4d63a3d491d11ffd8ac6" id="wp-hooks-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-includes/js/dist/i18n.min.js?ver=5e580eb46a90c2b997e6" id="wp-i18n-js"></script>
<script type="text/javascript" id="wp-i18n-js-after">
/* <![CDATA[ */
wp.i18n.setLocaleData( { 'text direction\u0004ltr': [ 'ltr' ] } );
/* ]]> */
</script>
<script type="text/javascript" id="wp-a11y-js-translations">
/* <![CDATA[ */
( function( domain, translations ) {
	var localeData = translations.locale_data[ domain ] || translations.locale_data.messages;
	localeData[""].domain = domain;
	wp.i18n.setLocaleData( localeData, domain );
} )( "default", {"translation-revision-date":"2025-07-30 21:52:12+0000","generator":"GlotPress\/4.0.1","domain":"messages","locale_data":{"messages":{"":{"domain":"messages","plural-forms":"nplurals=2; plural=n != 1;","lang":"en_CA"},"Notifications":["Notifications"]}},"comment":{"reference":"wp-includes\/js\/dist\/a11y.js"}} );
/* ]]> */
</script>
<script type="text/javascript" src="https://tools.cep.health/wp-includes/js/dist/a11y.min.js?ver=3156534cc54473497e14" id="wp-a11y-js"></script>
<script type="text/javascript" defer='defer' src="https://tools.cep.health/wp-content/plugins/gravityforms/js/jquery.json.min.js?ver=2.9.18" id="gform_json-js"></script>
<script type="text/javascript" id="gform_gravityforms-js-extra">
/* <![CDATA[ */
var gform_i18n = {"datepicker":{"days":{"monday":"Mo","tuesday":"Tu","wednesday":"We","thursday":"Th","friday":"Fr","saturday":"Sa","sunday":"Su"},"months":{"january":"January","february":"February","march":"March","april":"April","may":"May","june":"June","july":"July","august":"August","september":"September","october":"October","november":"November","december":"December"},"firstDay":1,"iconText":"Select date"}};
var gf_legacy_multi = [];
var gform_gravityforms = {"strings":{"invalid_file_extension":"This type of file is not allowed. Must be one of the following:","delete_file":"Delete this file","in_progress":"in progress","file_exceeds_limit":"File exceeds size limit","illegal_extension":"This type of file is not allowed.","max_reached":"Maximum number of files reached","unknown_error":"There was a problem while saving the file on the server","currently_uploading":"Please wait for the uploading to complete","cancel":"Cancel","cancel_upload":"Cancel this upload","cancelled":"Cancelled"},"vars":{"images_url":"https:\/\/tools.cep.health\/wp-content\/plugins\/gravityforms\/images"}};
var gf_global = {"gf_currency_config":{"name":"Canadian Dollar","symbol_left":"$","symbol_right":"CAD","symbol_padding":" ","thousand_separator":",","decimal_separator":".","decimals":2,"code":"CAD"},"base_url":"https:\/\/tools.cep.health\/wp-content\/plugins\/gravityforms","number_formats":[],"spinnerUrl":"https:\/\/tools.cep.health\/wp-content\/plugins\/gravityforms\/images\/spinner.svg","version_hash":"344e255594c2fd2b9abc4494dede5841","strings":{"newRowAdded":"New row added.","rowRemoved":"Row removed","formSaved":"The form has been saved.  The content contains the link to return and complete the form."}};
/* ]]> */
</script>
<script type="text/javascript" defer='defer' src="https://tools.cep.health/wp-content/plugins/gravityforms/js/gravityforms.min.js?ver=2.9.18" id="gform_gravityforms-js"></script>
<script type="text/javascript" id="gform_conditional_logic-js-extra">
/* <![CDATA[ */
var gf_legacy = {"is_legacy":""};
/* ]]> */
</script>
<script type="text/javascript" defer='defer' src="https://tools.cep.health/wp-content/plugins/gravityforms/js/conditional_logic.min.js?ver=2.9.18" id="gform_conditional_logic-js"></script>
<script type="text/javascript" defer='defer' src="https://tools.cep.health/wp-content/plugins/gravityforms/assets/js/dist/utils.min.js?ver=380b7a5ec0757c78876bc8a59488f2f3" id="gform_gravityforms_utils-js"></script>
<script type="text/javascript" defer='defer' src="https://tools.cep.health/wp-content/plugins/gravityforms/assets/js/dist/vendor-theme.min.js?ver=21e5a4db1670166692ac5745329bfc80" id="gform_gravityforms_theme_vendors-js"></script>
<script type="text/javascript" id="gform_gravityforms_theme-js-extra">
/* <![CDATA[ */
var gform_theme_config = {"common":{"form":{"honeypot":{"version_hash":"344e255594c2fd2b9abc4494dede5841"},"ajax":{"ajaxurl":"https:\/\/tools.cep.health\/wp-admin\/admin-ajax.php","ajax_submission_nonce":"d442579d84","i18n":{"step_announcement":"Step %1$s of %2$s, %3$s","unknown_error":"There was an unknown error processing your request. Please try again."}}}},"hmr_dev":"","public_path":"https:\/\/tools.cep.health\/wp-content\/plugins\/gravityforms\/assets\/js\/dist\/","config_nonce":"dc33aad5c3"};
/* ]]> */
</script>
<script type="text/javascript" defer='defer' src="https://tools.cep.health/wp-content/plugins/gravityforms/assets/js/dist/scripts-theme.min.js?ver=8fa5e6390c795318e567cd2b080e169b" id="gform_gravityforms_theme-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-content/themes/cep-tools/assets/js/app/modules/slider.js?ver=6.4.2" id="block-acf-drug-options-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-content/plugins/optinmonster/assets/dist/js/helper.min.js?ver=2.16.20" id="optinmonster-wp-helper-js"></script>
<script type="text/javascript">
/* <![CDATA[ */
 gform.initializeOnLoaded( function() { jQuery(document).on('gform_post_render', function(event, formId, currentPage){if(formId == 42) {gf_global["number_formats"][42] = {"35":{"price":false,"value":false},"1":{"price":false,"value":false},"2":{"price":false,"value":false},"20":{"price":false,"value":false},"8":{"price":false,"value":false},"4":{"price":false,"value":false},"16":{"price":false,"value":false},"14":{"price":false,"value":false},"11":{"price":false,"value":false},"15":{"price":false,"value":false},"13":{"price":false,"value":false},"12":{"price":false,"value":false},"19":{"price":false,"value":false},"28":{"price":false,"value":false},"23":{"price":false,"value":false},"21":{"price":false,"value":false},"24":{"price":false,"value":false},"25":{"price":false,"value":false},"26":{"price":false,"value":false},"27":{"price":false,"value":false},"18":{"price":false,"value":false}};if(window['jQuery']){if(!window['gf_form_conditional_logic'])window['gf_form_conditional_logic'] = new Array();window['gf_form_conditional_logic'][42] = { logic: { 8: {"field":{"enabled":true,"actionType":"show","logicType":"all","rules":[{"fieldId":"2","operator":"is","value":"A1C less than 1.5% above target"}]},"nextButton":null,"section":null},4: {"field":{"enabled":true,"actionType":"show","logicType":"all","rules":[{"fieldId":"2","operator":"is","value":"A1C greater than or equal to 1.5% above target"}]},"nextButton":null,"section":null},16: {"field":{"enabled":true,"actionType":"show","logicType":"all","rules":[{"fieldId":"2","operator":"is","value":"Symptomatic hyperglycemia <br> and\/or metabolic decompensation*"}]},"nextButton":null,"section":null},14: {"field":{"enabled":true,"actionType":"show","logicType":"any","rules":[{"fieldId":"2","operator":"is","value":""}]},"nextButton":null,"section":null},11: {"field":{"enabled":true,"actionType":"show","logicType":"all","rules":[{"fieldId":"14","operator":"is","value":"at 3 months"}]},"nextButton":null,"section":null},15: {"field":{"enabled":true,"actionType":"show","logicType":"all","rules":[{"fieldId":"14","operator":"is","value":"4-6 months or change in clinical status"}]},"nextButton":null,"section":null},13: {"field":{"enabled":true,"actionType":"show","logicType":"any","rules":[{"fieldId":"14","operator":"is","value":"at 3 months"},{"fieldId":"14","operator":"is","value":"4-6 months or change in clinical status"}]},"nextButton":null,"section":null},12: {"field":{"enabled":true,"actionType":"show","logicType":"any","rules":[{"fieldId":"14","operator":"is","value":"at 3 months"},{"fieldId":"14","operator":"is","value":"4-6 months or change in clinical status"}]},"nextButton":null,"section":null},19: {"field":{"enabled":true,"actionType":"show","logicType":"all","rules":[{"fieldId":"12","operator":"is","value":"No"}]},"nextButton":null,"section":null},28: {"field":{"enabled":true,"actionType":"show","logicType":"all","rules":[{"fieldId":"12","operator":"is","value":"Yes"}]},"nextButton":null,"section":null},23: {"field":{"enabled":true,"actionType":"show","logicType":"any","rules":[{"fieldId":"2","operator":"is","value":"A1C less than 1.5% above target"},{"fieldId":"2","operator":"is","value":"A1C greater than or equal to 1.5% above target"}]},"nextButton":null,"section":null},21: {"field":{"enabled":true,"actionType":"show","logicType":"all","rules":[{"fieldId":"23","operator":"is","value":"at 3 months"}]},"nextButton":null,"section":null},24: {"field":{"enabled":true,"actionType":"show","logicType":"all","rules":[{"fieldId":"23","operator":"is","value":"4-6 months or change in clinical status"}]},"nextButton":null,"section":null},25: {"field":{"enabled":true,"actionType":"show","logicType":"any","rules":[{"fieldId":"23","operator":"is","value":"at 3 months"},{"fieldId":"23","operator":"is","value":"4-6 months or change in clinical status"}]},"nextButton":null,"section":null},26: {"field":{"enabled":true,"actionType":"show","logicType":"any","rules":[{"fieldId":"23","operator":"is","value":"at 3 months"},{"fieldId":"23","operator":"is","value":"4-6 months or change in clinical status"}]},"nextButton":null,"section":null},27: {"field":{"enabled":true,"actionType":"show","logicType":"all","rules":[{"fieldId":"26","operator":"is","value":"No"}]},"nextButton":null,"section":null},18: {"field":{"enabled":true,"actionType":"show","logicType":"all","rules":[{"fieldId":"26","operator":"is","value":"Yes"}]},"nextButton":null,"section":null} }, dependents: { 8: [8],4: [4],16: [16],14: [14],11: [11],15: [15],13: [13],12: [12],19: [19],28: [28],23: [23],21: [21],24: [24],25: [25],26: [26],27: [27],18: [18] }, animation: 0, defaults: [], fields: {"35":[],"1":[],"2":[8,4,16,14,23],"20":[],"8":[],"4":[],"16":[],"14":[11,15,13,12],"11":[],"15":[],"13":[],"12":[19,28],"19":[],"28":[],"23":[21,24,25,26],"21":[],"24":[],"25":[],"26":[27,18],"27":[],"18":[]} }; if(!window['gf_number_format'])window['gf_number_format'] = 'decimal_dot';jQuery(document).ready(function(){gform.utils.trigger({ event: 'gform/conditionalLogic/init/start', native: false, data: { formId: 42, fields: null, isInit: true } });window['gformInitPriceFields']();gf_apply_rules(42, [8,4,16,14,11,15,13,12,19,28,23,21,24,25,26,27,18], true);jQuery('#gform_wrapper_42').show();jQuery('#gform_wrapper_42 form').css('opacity', '');jQuery(document).trigger('gform_post_conditional_logic', [42, null, true]);gform.utils.trigger({ event: 'gform/conditionalLogic/init/end', native: false, data: { formId: 42, fields: null, isInit: true } });} );} 				gform.utils.addAsyncFilter('gform/submission/pre_submission', async (data) => {
				    const input = document.createElement('input');
				    input.type = 'hidden';
				    input.name = 'gf_zero_spam_key';
				    input.value = 'eSao19U6Ru3mxtRwzSlgciWT7M2PVdhHBjeoqT5t2qW5b8rUmZoumjcIMrRTnrnU';
				    input.setAttribute('autocomplete', 'new-password');
				    data.form.appendChild(input);
				
				    return data;
				});} } );jQuery(document).on('gform_post_conditional_logic', function(event, formId, fields, isInit){} ) } ); 
/* ]]> */
</script>
<script type="text/javascript">
/* <![CDATA[ */
 gform.initializeOnLoaded( function() {jQuery(document).trigger("gform_pre_post_render", [{ formId: "42", currentPage: "1", abort: function() { this.preventDefault(); } }]);        if (event && event.defaultPrevented) {                return;        }        const gformWrapperDiv = document.getElementById( "gform_wrapper_42" );        if ( gformWrapperDiv ) {            const visibilitySpan = document.createElement( "span" );            visibilitySpan.id = "gform_visibility_test_42";            gformWrapperDiv.insertAdjacentElement( "afterend", visibilitySpan );        }        const visibilityTestDiv = document.getElementById( "gform_visibility_test_42" );        let postRenderFired = false;        function triggerPostRender() {            if ( postRenderFired ) {                return;            }            postRenderFired = true;            gform.core.triggerPostRenderEvents( 42, 1 );            if ( visibilityTestDiv ) {                visibilityTestDiv.parentNode.removeChild( visibilityTestDiv );            }        }        function debounce( func, wait, immediate ) {            var timeout;            return function() {                var context = this, args = arguments;                var later = function() {                    timeout = null;                    if ( !immediate ) func.apply( context, args );                };                var callNow = immediate && !timeout;                clearTimeout( timeout );                timeout = setTimeout( later, wait );                if ( callNow ) func.apply( context, args );            };        }        const debouncedTriggerPostRender = debounce( function() {            triggerPostRender();        }, 200 );        if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) {            const observer = new MutationObserver( ( mutations ) => {                mutations.forEach( ( mutation ) => {                    if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) {                        debouncedTriggerPostRender();                        observer.disconnect();                    }                });            });            observer.observe( document.body, {                attributes: true,                childList: false,                subtree: true,                attributeFilter: [ 'style', 'class' ],            });        } else {            triggerPostRender();        }    } ); 
/* ]]> */
</script>
		<script type="text/javascript">var omapi_localized = {
			ajax: 'https://tools.cep.health/wp-admin/admin-ajax.php?optin-monster-ajax-route=1',
			nonce: '54d7109d0e',
			slugs:
			{"hhgajtyemrlknjsvrsd5":{"slug":"hhgajtyemrlknjsvrsd5","mailpoet":false},"tkia37pcyyahx6opqim2":{"slug":"tkia37pcyyahx6opqim2","mailpoet":false},"ngtztpck7tvpbcvakl7d":{"slug":"ngtztpck7tvpbcvakl7d","mailpoet":false},"f2bzjhvjmeyfqkxxjggz":{"slug":"f2bzjhvjmeyfqkxxjggz","mailpoet":false},"qgchslypk4toxdtgsfsf":{"slug":"qgchslypk4toxdtgsfsf","mailpoet":false},"cfontzigzdapzyxtbhg4":{"slug":"cfontzigzdapzyxtbhg4","mailpoet":false},"nflzw9az1mcray2ltc4m":{"slug":"nflzw9az1mcray2ltc4m","mailpoet":false},"edlo1w0s0lujgciyjgf9":{"slug":"edlo1w0s0lujgciyjgf9","mailpoet":false},"ybbyul2ujyofvsznkiti":{"slug":"ybbyul2ujyofvsznkiti","mailpoet":false},"doewskxay35gb860nodl":{"slug":"doewskxay35gb860nodl","mailpoet":false},"wm0xaeyycxvhthxjz76n":{"slug":"wm0xaeyycxvhthxjz76n","mailpoet":false},"iqff27bs0pszfabitkgw":{"slug":"iqff27bs0pszfabitkgw","mailpoet":false},"xfup8pda84l5bd0udyje":{"slug":"xfup8pda84l5bd0udyje","mailpoet":false},"xokl1h6esysgo5wdkq9d":{"slug":"xokl1h6esysgo5wdkq9d","mailpoet":false},"jaxkt0icjnuu0z43iuik":{"slug":"jaxkt0icjnuu0z43iuik","mailpoet":false},"vso3vlstnsfjgeuogzry":{"slug":"vso3vlstnsfjgeuogzry","mailpoet":false},"awihu5noxqqj5s7iasv8":{"slug":"awihu5noxqqj5s7iasv8","mailpoet":false},"cdikvvptidch9oj1o56k":{"slug":"cdikvvptidch9oj1o56k","mailpoet":false},"qeu7gqedkzjnotzskhln":{"slug":"qeu7gqedkzjnotzskhln","mailpoet":false},"okkbvdzprjjylm7wjkhe":{"slug":"okkbvdzprjjylm7wjkhe","mailpoet":false},"rxekv8i4pwnmp4zvclcm":{"slug":"rxekv8i4pwnmp4zvclcm","mailpoet":false},"koz3ranojk5yi8c5wmpe":{"slug":"koz3ranojk5yi8c5wmpe","mailpoet":false},"e6m4njfonyv93sqcttlx":{"slug":"e6m4njfonyv93sqcttlx","mailpoet":false}}		};</script>
				<script type="text/javascript">var omapi_data = {"object_id":58846,"object_key":"tools","object_type":"post","term_ids":[],"wp_json":"https:\/\/tools.cep.health\/wp-json","wc_active":false,"edd_active":false,"nonce":"9051981ff5"};</script>
		
  </body>
</html>
